{"gene":"TREM1","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":2007,"finding":"TREM-1 constitutively associates with DAP12, an ITAM-bearing adapter protein, which is required for induction of intracellular signaling downstream of TREM-1 in monocytes and neutrophils. DAP12 phosphorylation following TREM-1 activation leads to production of pro-inflammatory cytokines, chemokines, and reactive oxygen species, and triggers rapid degranulation and phagocytosis.","method":"Biochemical and functional assays in monocytes and neutrophils; review synthesizing prior experimental work","journal":"Immunology letters","confidence":"High","confidence_rationale":"Tier 2 / Strong — constitutive TREM-1/DAP12 association replicated across multiple independent labs and studies; functional consequences (cytokine production, ROS, degranulation) established by multiple orthogonal approaches","pmids":["18192027","23108097"],"is_preprint":false},{"year":2007,"finding":"A TREM-1 ligand is expressed on human platelets. Using a recombinant TREM-1 fusion protein, specific binding of TREM-1 to platelets was demonstrated. TREM-1/ligand interaction on platelets is required for platelet-induced augmentation of PMN effector functions (provoked by LPS), but not for platelet/PMN complex formation (which depends on integrins and selectins).","method":"Recombinant TREM-1 fusion protein binding assay; functional PMN activation assays with platelet co-culture; TREM-1 blocking","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding demonstrated with fusion protein, functional consequence shown with blocking; single lab, two orthogonal methods","pmids":["17452516"],"is_preprint":false},{"year":2009,"finding":"TREM-1-induced oxidative burst in human PMN requires phosphatidyl inositide 3-kinase (PI3K), phospholipase C, and p38MAPK. Protein kinase B (AKT) and ERK show characteristic phosphorylation patterns upon TREM-1 or TLR4 single or co-ligation, indicating individual activation pathways that synergize.","method":"Pharmacological inhibitors of PI3K, PLC, p38MAPK; Western blot analysis of AKT and ERK phosphorylation; oxidative burst assay in human PMN","journal":"Journal of innate immunity","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro kinase/signaling assay with pharmacological inhibitors and Western blot, single lab, multiple orthogonal methods","pmids":["20375613"],"is_preprint":false},{"year":2011,"finding":"TREM-1 interacts with or is a component of the TLR4/LPS receptor complex in human neutrophils. Blocking anti-TREM-1 antibodies inhibited LPS-induced TNF-α production, and blocking TLR4 reduced the effects of TREM-1 cross-linking; co-localization of TREM-1 and TLR4 was observed.","method":"Blocking antibodies against TREM-1 and TLR4; TLR4-specific inhibitor; co-localization by immunofluorescence in human neutrophils; cytokine measurement","journal":"European cytokine network","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-localization plus reciprocal blocking experiments in primary human cells; single lab, two orthogonal approaches","pmids":["21393102"],"is_preprint":false},{"year":2015,"finding":"TREM-1 expression is upregulated in ischemic myocardium after MI. Trem-1 genetic invalidation or pharmacological inhibition (LR12 peptide) dampens myocardial inflammation, limits neutrophil recruitment and MCP-1 production, reduces classical monocyte mobilization to the heart, improves left ventricular function and survival. Soluble TREM-1 (sTREM-1) is detectable in plasma of acute MI patients.","method":"Trem-1 knockout mice; pharmacological inhibition with LR12 peptide; FDG-PET imaging; conductance catheter studies; n=20-22 per group","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO plus pharmacological inhibition in multiple MI models with defined cellular and functional phenotypes; replicated across permanent and transient ischemia models","pmids":["25840803"],"is_preprint":false},{"year":2016,"finding":"Trem-1 genetic invalidation in chimeric Ldlr-/- and ApoE-/-/Trem-1-/- mice reduces atherosclerotic plaque size and inflammation, alters monocyte recruitment into lesions, and inhibits TLR4-initiated macrophage responses. TREM-1 plays a critical role in upregulation of CD36, thereby promoting inflammatory foam cell formation. Pharmacological blockade with LR12 peptide similarly reduces atherosclerosis.","method":"Bone marrow chimera mice (Trem-1-/-); ApoE-/-Trem-1-/- double KO; LR12 pharmacological blockade; histology; flow cytometry; gene expression","journal":"Journal of the American College of Cardiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic invalidation replicated in two different KO models plus pharmacological blockade, with multiple orthogonal readouts; independently supported by a second study in the same year","pmids":["28007141"],"is_preprint":false},{"year":2016,"finding":"TREM-1 is highly upregulated under dyslipidemic conditions on circulating and lesion-infiltrating myeloid cells. TREM-1 promotes atherosclerosis by synergizing with HFCD serum-derived factors to promote pro-inflammatory cytokine responses and foam cell formation, and by skewing monocyte differentiation and enhancing lipid accumulation. Trem1-/-/Apoe-/- mice exhibit substantially attenuated diet-induced atherogenesis.","method":"Trem1-/-/Apoe-/- double KO mice; human monocyte/macrophage culture with HFCD serum; cytokine assays; histology","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO model plus in vitro mechanistic studies; independent replication of TREM-1 pro-atherogenic role in a separate lab from PMID:28007141","pmids":["27762264"],"is_preprint":false},{"year":2016,"finding":"TREM1 facilitates microglial phagocytosis of amyloid-β. Knockdown of Trem1 in mouse primary microglia decreased Aβ phagocytosis; overexpression or agonistic antibody activation increased phagocytosis and reduced Aβ burden. Trem1 knockdown in APP/PSEN1 mice increased Aβ1-42 levels and total amyloid burden; selective overexpression on microglia ameliorated Aβ neuropathology and rescued spatial cognitive impairments.","method":"Trem1 knockdown and overexpression in primary mouse microglia; in vivo AAV-mediated expression in APP/PSEN1 mice; agonistic TREM1 antibody; Aβ phagocytosis assays; spatial memory tests","journal":"Acta neuropathologica","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function and gain-of-function both in vitro and in vivo, multiple orthogonal methods including behavioral outcomes; single lab but comprehensive","pmids":["27670763"],"is_preprint":false},{"year":2018,"finding":"TREM-1 is activated by multimerization/clustering at the cell surface. Levels of intracellular Ca2+ release, ROS, and cytokine production correlate with the degree of TREM-1 aggregation. LPS induces a two-step process in monocytes: upregulation then clustering of TREM-1; in neutrophils LPS induces rapid membrane reorganization of TREM-1. The ectodomain of TREM-1 homooligomerizes in a concentration-dependent manner. DAP12 stabilizes TREM-1 surface expression and multimerization. TREM-1 inhibitor LR12 limits TREM-1 multimerization, supporting ligand-induced, receptor-mediated dimerization.","method":"Native mass spectrometry; Ca2+ flux assays; ROS assays; cytokine ELISA; flow cytometry on primary human monocytes and neutrophils; TREM-1 ectodomain oligomerization in vitro","journal":"Cellular & molecular immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of ectodomain oligomerization plus native MS, combined with cellular functional assays; single lab but multiple orthogonal methods","pmids":["29568119"],"is_preprint":false},{"year":2018,"finding":"TREM-1 promotes liver injury and fibrosis by intensifying hepatic inflammation. TREM-1 expression is limited to liver macrophages/monocytes and is upregulated on Kupffer cells in CCl4-induced chronic liver injury. TREM-1 signaling promotes pro-inflammatory cytokine production and inflammatory cell mobilization to injury sites. Reconstitution of Trem1-deficient mice with Trem1-sufficient Kupffer cells restored recruitment of inflammatory monocytes and severity of liver injury, establishing TREM-1 as a master regulator of Kupffer cell activation that activates hepatic stellate cells.","method":"Trem1 knockout mice; Kupffer cell reconstitution experiment; CCl4 chronic liver injury model; flow cytometry; histology; cytokine measurement","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO plus cell reconstitution experiment establishing cell-autonomous Kupffer cell role; multiple orthogonal methods","pmids":["30137027"],"is_preprint":false},{"year":2018,"finding":"TREM-1 inhibition restores impaired autophagy activity (macroautophagy and CMA) and reduces ER stress (UPR) in colitis. TREM-1 inhibition (pharmacological LR12 or genetic KO) increased ATG1/ULK-1, ATG13, ATG5, ATG16L1, MAP1LC3-I/II, HSPA8, HSP90AA1 and decreased PERK, IRE-1α, ATF-6α expression in colitic mice. TREM-1 inhibition also prevented dysbiosis.","method":"LR12 pharmacological inhibition; Trem-1 KO mice; DSS colitis model; Western blotting for autophagy and UPR markers; MiSeq microbiota sequencing","journal":"Journal of Crohn's & colitis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO and pharmacological inhibition with Western blot protein-level mechanistic readouts; single lab, two complementary approaches","pmids":["28961797"],"is_preprint":false},{"year":2019,"finding":"TREM-1 interacts directly with spleen tyrosine kinase (SYK) in microglia. TREM-1 activates downstream pro-inflammatory pathways CARD9/NF-κB and NLRP3/caspase-1 through SYK interaction. TREM-1-induced SYK activation promotes microglial pyroptosis by elevating gasdermin D (GSDMD) and its N-terminal fragment (GSDMD-N), forming pores that release intracellular inflammatory factors.","method":"Co-immunoprecipitation (TREM-1/SYK interaction); Western blot for pathway components; in vivo MCAO mouse model and in vitro microglial cultures; LP17 pharmacological inhibition","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP demonstrated interaction, supported by in vivo and in vitro functional data; single lab","pmids":["31324751"],"is_preprint":false},{"year":2019,"finding":"Peripheral CD11b+CD45+ myeloid TREM1 induction amplifies stroke injury via pro-inflammatory innate immune activation. Following stroke, noradrenergic-dependent increases in gut permeability induce TREM1 on Ly6C+MHCII+ intestinal lamina propria macrophages, further increasing epithelial permeability and facilitating bacterial translocation. Genetic or pharmacological TREM1 inhibition improved outcome via antioxidant and anti-inflammatory mechanisms.","method":"TREM1 genetic KO; pharmacological inhibition; PET imaging with radiolabeled anti-TREM1 antibody; trafficking studies; intestinal permeability assays in MCAO stroke model","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO plus pharmacological inhibition plus PET imaging; multiple orthogonal methods; published in high-impact journal","pmids":["31263278"],"is_preprint":false},{"year":2019,"finding":"TREM1 protects HIV-1-infected macrophages from apoptosis through maintenance of mitochondrial function. Upon HIV infection, TREM1 expression increases along with BCL2, BCLXL, MFN1, MFN2 and BIM translocation to mitochondria. TREM1 silencing in HIV-infected macrophages decreased BCL2, BCLXL, MFN1, MFN2, increased BAD and BAX, causing disruption of mitochondrial membrane potential (Δψm), cytochrome c release, caspase 9 cleavage, and apoptosis. HIV Tat, gp120, and TLR8 agonist RNA40 recapitulate these effects.","method":"TREM1 siRNA silencing in HIV-infected macrophages; mitochondrial membrane potential assay; cytochrome c release; Western blot for BCL2 family proteins; apoptosis assays","journal":"mBio","confidence":"High","confidence_rationale":"Tier 2 / Moderate — loss-of-function (siRNA) with multiple mechanistic readouts (mitochondrial potential, cytochrome c, caspase cleavage, apoptosis) establishing pathway position; single lab but multiple orthogonal methods","pmids":["31719184"],"is_preprint":false},{"year":2019,"finding":"TREM-1 regulates neutrophil chemotaxis by promoting NOX2-dependent superoxide production. Trem1-deficient peritoneal neutrophils show impaired NOX2-dependent superoxide production (measured by EPR spectroscopy) and reduced oxygen consumption. TREM-1-deficient neutrophils have impaired directional migration toward fMLP and zymosan-activated serum. TREM-1 regulates neutrophil migratory properties in part by promoting AKT activation and NOX2-dependent superoxide production.","method":"Trem1 knockout mice; electron paramagnetic resonance spectroscopy for superoxide; Clark electrode for oxygen consumption; directional migration assay; AKT phosphorylation by Western blot","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO with multiple orthogonal mechanistic readouts (EPR, Clark electrode, migration, Western blot); single lab, comprehensive mechanistic dissection","pmids":["30667543"],"is_preprint":false},{"year":2020,"finding":"TREM-1 triggers microglial pyroptosis via activating NLRP3 inflammasome following subarachnoid hemorrhage. Recombinant TREM-1 (mimic) worsened outcomes, while LP17 antagonist ameliorated pyroptosis by diminishing GSDMD-N and IL-1β production in microglia. Mechanistically confirmed both in vivo (SAH mouse model) and in vitro.","method":"Intranasal LP17 administration; recombinant TREM-1 administration; SAH mouse model; Western blot for NLRP3, caspase-1, GSDMD, GSDMD-N, IL-1β; in vitro microglial cultures","journal":"Translational stroke research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological gain- and loss-of-function in vivo and in vitro with protein-level mechanistic endpoints; single lab","pmids":["32862402"],"is_preprint":false},{"year":2020,"finding":"Extracellular CIRP (eCIRP) activates TREM-1 on neutrophils, which generates ICAM-1+ neutrophils. ICAM-1+ neutrophils then promote NET formation via Rho GTPase activation. TREM-1-/- neutrophils or LP17-pretreated neutrophils showed significantly decreased ICAM-1 expression after rmCIRP treatment. Blockade of ICAM-1 significantly decreased Rho activation and NET formation.","method":"TREM-1-/- mice; LP17 pharmacological inhibition; rmCIRP injection; flow cytometry; Rho activation assay; NET quantification; ICAM-1 blocking antibody","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO and pharmacological inhibition with defined downstream signaling (Rho/ICAM-1/NETosis); single lab, multiple orthogonal methods","pmids":["32506691"],"is_preprint":false},{"year":2020,"finding":"TREM-1 activation in macrophages induces endoplasmic reticulum stress through the IRE-1α/XBP-1s pathway. Agonistic anti-TREM-1 antibody increased expression of ER stress markers (ATF6, PERK, IRE-1α, XBP-1s) and pro-inflammatory cytokines. Inhibiting IRE-1α/XBP-1s with STF-083010 or XBP-1 silencing attenuated TREM-1-induced cytokine production. TREM-1 blockade (LR12) ameliorated ER stress in vitro and in vivo.","method":"Agonistic anti-TREM-1 antibody; STF-083010 IRE-1α inhibitor; XBP-1 siRNA silencing; 4-PBA ER stress inhibitor; Western blot; primary macrophage cultures; LPS-induced ALI mouse model","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — agonist antibody plus pathway inhibitors plus gene silencing with multiple protein-level readouts; single lab","pmids":["33957479"],"is_preprint":false},{"year":2020,"finding":"Tryptophanyl-tRNA synthetase 1 (WARS1) activates TREM-1 expression at both mRNA and protein levels via TLR2 and TLR4, mediated by both MyD88 and TRIF. Targeted deletion of TLR4, TLR2, MyD88, and TRIF abrogated TREM-1 activation. WARS1 promoted TREM-1 downstream phosphorylation of DAP12, Syk, and AKT. Knockdown of TREM-1 or inhibition of Syk suppressed the inflammatory signaling loop (p38 MAPK, ERK, NF-κB), reducing cytokine production.","method":"TLR4/TLR2/MyD88/TRIF knockout cells; TREM-1 knockdown; Syk kinase inhibitor; Western blot for DAP12, Syk, AKT phosphorylation; cytokine ELISA","journal":"Biomolecules","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic KO cell lines plus TREM-1 knockdown with defined phosphoprotein readouts; single lab, multiple orthogonal approaches","pmids":["32899943"],"is_preprint":false},{"year":2021,"finding":"TREM-1 orchestrates angiotensin II-induced monocyte trafficking and promotes abdominal aortic aneurysm. TREM-1 on Ly6Chi monocytes is activated by AngII via AT1R signaling. Antibody-mediated TREM-1 stimulation exacerbated Ly6Chi monocyte aorta infiltration via CD62L upregulation. Trem1 gene deletion attenuated aortic inflammation (reduced Il1b, Tnfa, Mmp2, Mmp9 mRNA) and macrophage content.","method":"Apoe-/-Trem1-/- mice; AngII-induced AAA model; LR12 pharmacological blockade; anti-TREM-1 stimulating antibody; flow cytometry; qRT-PCR","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO, pharmacological inhibition, and gain-of-function (agonist antibody) in the same model; multiple orthogonal methods","pmids":["33258804"],"is_preprint":false},{"year":2021,"finding":"TREM-1 regulates macrophage M1 polarization via the STAT3/HIF-1α signaling pathway. Knockdown of Trem1 in RAW 264.7 cells decreased M1 polarization and increased M2 polarization; overexpression had the opposite effect. Trem1 knockout mice showed limited macrophage infiltration and decreased M1 gene expression in periodontitis lesions.","method":"Trem1 siRNA knockdown and overexpression in RAW 264.7 macrophages; Trem1 KO mice; flow cytometry; Western blotting; RT-qPCR; RNA sequencing identifying STAT3/HIF-1α pathway","journal":"Journal of dental research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO in vivo plus loss- and gain-of-function in vitro with pathway identification by RNA-seq; single lab","pmids":["34719965"],"is_preprint":false},{"year":2021,"finding":"TREM-1 cooperates with diminished DNA damage response to promote pre-leukemia stem cell (pre-LSC) expansion in Fanconi anemia. shRNA knockdown of Trem1 in Fanca-/- pre-LSCs improved leukemia-related survival but did not affect DDR or genomic instability, placing TREM-1 downstream or parallel to DDR in leukemogenic transformation.","method":"Trem1 shRNA knockdown; Fanca-/- mouse model; in vivo transplantation; survival analysis; gene expression profiling","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined in vivo phenotype and epistasis analysis; single lab","pmids":["27568523"],"is_preprint":false},{"year":2022,"finding":"TREM-1 induces cardiomyocyte pyroptosis via NLRP3 inflammasome activation through the SMC4/NEMO pathway in sepsis. TREM-1 and SMC4 were found to interact closely. Inhibition of TREM-1 or SMC4 prevented NLRP3 upregulation and decreased Gasdermin-D, IL-1β and caspase-1 cleavage in HL-1 cardiomyocytes. LR12 in CLP mice decreased NLRP3 expression and attenuated pyroptosis, improving cardiac function and survival.","method":"Co-immunoprecipitation (TREM-1/SMC4 interaction); siRNA inhibition of TREM-1 and SMC4; LPS/nigericin-stimulated HL-1 cells; CLP sepsis mouse model; LR12 peptide; Western blot","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifying SMC4 interaction plus in vitro and in vivo functional validation; single lab, multiple orthogonal methods","pmids":["36181338"],"is_preprint":false},{"year":2022,"finding":"TREM-1 exacerbates pulmonary fibrosis by promoting alveolar epithelial cell (AEC) senescence. TREM-1 was upregulated in AECs (not just macrophages) in bleomycin-treated mice and correlated with senescence markers. Agonistic TREM-1 antibody exacerbated BLM-induced senescence in MLE12 cells; blockade with LR12 reduced p16, p21, p53, γ-H2AX expression and attenuated fibrosis.","method":"LR12 prophylactic and therapeutic blockade; agonistic TREM-1 antibody in MLE12 cells; BLM-induced PF mouse model; Western blot for senescence markers; histology","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function (agonist antibody) and loss-of-function (LR12) in both in vitro and in vivo models with protein-level mechanistic readouts; single lab","pmids":["36330909"],"is_preprint":false},{"year":2022,"finding":"TREM-1 activation in macrophages promotes NLRP3 inflammasome activation through metabolic reprogramming: TREM-1 activation enhances glycolysis and inhibits oxidative phosphorylation via the PI3K/AKT/mTOR pathway, leading to HIF-1α accumulation and nuclear translocation, which drives glycolysis-dependent NLRP3/caspase-1 activation. Inhibiting mTOR, HIF-1α, or glycolysis (2-DG) suppressed TREM-1-induced NLRP3 activation.","method":"TREM-1 agonist antibody; 2-deoxyglucose glycolysis inhibition; mTOR inhibitor rapamycin; HIF-1α inhibitor; glucose consumption assay; Western blot; LPS-induced ALI mouse model; LR12 blockade","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway inhibitors combined with agonist activation establishing metabolic-to-inflammasome signaling axis; single lab, multiple orthogonal methods","pmids":["36594089"],"is_preprint":false},{"year":2022,"finding":"Endothelial TREM-1 signals via SYK/β-catenin pathway to regulate blood-brain barrier integrity after intracerebral hemorrhage. TREM-1 activation reduces β-catenin, claudin-5, and ZO-1 expression. SYK activation CRISPR abolished the beneficial effect of TREM-1 blockade on junction molecules; the SYK inhibitor R406 reversed the impact of TREM-1 agonist on β-catenin, claudin-5, and ZO-1 downregulation.","method":"LP17 intranasal administration; SYK activation CRISPR intracerebroventricularly; anti-TREM-1 agonist IgG; SYK inhibitor R406; ICH collagenase mouse model; Western blot; BBB permeability assay","journal":"CNS neuroscience & therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal gain- and loss-of-function with SYK genetic activation and pharmacological inhibition establishing pathway; single lab","pmids":["37170484"],"is_preprint":false},{"year":2022,"finding":"eCIRP activates TREM-1 on renal endothelial cells to induce AKI. TREM-1-/- mice had attenuated AKI and reduced ICAM-1 expression in renal tissue after rmCIRP injection. TREM-1 inhibitory peptide M3 attenuated human renal glomerular endothelial cell activation (cytokine production and sTREM-1 release) after eCIRP stimulation.","method":"TREM-1-/- mice; rmCIRP injection; M3 inhibitory peptide; primary human renal glomerular endothelial cell culture; serum BUN/creatinine/NGAL measurement; mRNA and protein expression","journal":"Frontiers in physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO and pharmacological inhibition in vivo and in vitro; multiple injury biomarkers; single lab","pmids":["36246143"],"is_preprint":false},{"year":2023,"finding":"TREM-1 triggers macrophage necroptosis through mTOR-dependent mitochondrial fission during ALI. TREM-1 activation (agonist anti-TREM-1 Ab) induced necroptosis in macrophages. mTOR signaling promotes TREM-1-mediated DRP1Ser616 phosphorylation, causing surplus mitochondrial fission leading to necroptosis. Inhibiting mTOR (rapamycin), DRP1 (Mdivi-1), or RIPK3 (GSK872) all reduced TREM-1-triggered necroptosis.","method":"Agonist anti-TREM-1 antibody; RIPK3 inhibitor GSK872; DRP1 inhibitor Mdivi-1; mTOR inhibitor rapamycin; LR12 in LPS-induced ALI mice; Western blot for DRP1Ser616 phosphorylation; necroptosis assays","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — agonist plus multiple pathway inhibitors establishing mTOR-DRP1-necroptosis axis; single lab, multiple orthogonal methods","pmids":["36879273"],"is_preprint":false},{"year":2023,"finding":"Accumulated lipid droplets (LDs) in microglia co-localize with TREM1, resulting in TREM1 buildup. TREM1 accumulation in turn aggravates HG-induced lipophagy damage and promotes neuroinflammatory cascades via NLRP3 inflammasome. LP17 blockade of TREM1 inhibited LD and TREM1 accumulation and reduced hippocampal neuronal inflammatory damage.","method":"Co-immunoprecipitation (LDs/TREM1 co-localization); db/db and HFD/STZ mouse models; LP17 pharmacological blockade; HG-treated BV2, HMC3 and primary microglia; Western blot; immunofluorescence; behavioral tests","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus pharmacological blockade in multiple in vivo models with defined mechanistic pathway; single lab","pmids":["37204119"],"is_preprint":false},{"year":2023,"finding":"TREM1 promotes gastric cancer progression through NETs-mediated M2 macrophage polarization. TREM1 deficiency hindered tumor growth, reduced neutrophil infiltration, reduced NETs formation, and stimulated M1 (rather than M2) macrophage polarization. DNase-1 (NETs degrader) counteracted the impacts of TREM1 on GC, placing TREM1 upstream of NETs in this pathway.","method":"TREM1 KO and knock-in GC mice; MNNG-induced GC model; DNase-1 treatment; flow cytometry for macrophage polarization; immunofluorescence and Western blot for NETs markers; IHC","journal":"Digestive and liver disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO/KI plus epistasis experiment with DNase-1 placing TREM1 upstream of NETs; single lab","pmids":["38151453"],"is_preprint":false},{"year":2023,"finding":"TREM1 in microglia is upregulated by HIV Tat through a TLR4/TICAM1/COX-2/PGE synthase/PGE2-dependent pathway. TREM1 silencing in HIV-infected microglia induces cell death without increased viral or pro-inflammatory cytokine expression.","method":"TREM1 siRNA silencing in HIV-infected human microglia; TLR4 blocking; COX-2 and PGE2 pathway inhibitors; apoptosis assays; cytokine measurement","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic silencing plus pharmacological pathway inhibitors establishing the upstream regulatory mechanism; single lab, multiple orthogonal methods","pmids":["37326481"],"is_preprint":false},{"year":2024,"finding":"Trem1 deficiency prevents age-dependent changes in myeloid metabolism and inflammation. Trem1-deficient microglia are resistant to amyloid-β42 oligomer-induced bioenergetic changes in vitro. Trem1 haploinsufficiency in 5XFAD mice prevents spatial memory loss, preserves homeostatic microglial morphology, reduces neuritic dystrophy and disease-associated microglial transcriptomic signature changes. In aging APPSwe mice, Trem1 deficiency prevents hippocampal memory decline while restoring synaptic mitochondrial function and cerebral glucose uptake. TREM1 colocalizes with Iba1+ cells around amyloid plaques in postmortem AD brain.","method":"Trem1 KO and haploinsufficiency in 5XFAD and APPSwe mouse models; metabolomics (ribose 5-phosphate); in vitro bioenergetics assay; spatial memory testing; microglial morphology analysis; transcriptomics; PET imaging for glucose uptake; postmortem AD brain immunohistochemistry","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models (KO, haploinsufficiency) in two different AD mouse models plus in vitro mechanistic assays and postmortem human validation; multiple orthogonal methods","pmids":["38539014"],"is_preprint":false},{"year":2024,"finding":"TREM1 modulates M1 macrophage polarization via STAT3/HIF-1α axis. In microglia, TREM1 regulates NLRP3 activation via the NF-κB pathway: TREM1 overexpression activates NF-κB, upregulates NLRP3 components and pro-inflammatory cytokines; NF-κB inhibitor PDTC reversed this. TREM1 knockdown attenuated LPS-induced NF-κB pathway activation.","method":"TREM1 siRNA knockdown; TREM1 overexpression plasmid; NF-κB inhibitor PDTC; LPS-treated BV2 cells; Western blotting; immunofluorescence; NTG-induced chronic migraine mouse model; LR12 inhibition","journal":"The journal of headache and pain","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function and gain-of-function with pathway inhibitor rescue; in vitro and in vivo; single lab","pmids":["38177990"],"is_preprint":false},{"year":2024,"finding":"TREM1 aggravates microglial ferroptosis through the PERK pathway of endoplasmic reticulum stress in diabetes-associated cognitive impairment. High glucose activates the PERK-ERS pathway; TREM1 inhibition with LP17 or PERK inhibitor GSK2606414 reversed ferroptosis (iron accumulation, GSH/GSSG reduction, lipid peroxidation, ROS) in BV2/HMC3 microglia and in vivo.","method":"LP17 pharmacological blockade; PERK inhibitor GSK2606414; HG-treated BV2 and HMC3 cells; HFD/STZ mouse model; Prussian blue staining for iron; Western blot; transmission electron microscopy; Y-maze and NOR behavioral tests","journal":"Experimental neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological blockade of TREM1 and PERK showing pathway interdependence; in vitro and in vivo; single lab, multiple orthogonal methods","pmids":["39461708"],"is_preprint":false},{"year":2024,"finding":"In glioblastoma, hypoxia-induced TREM1 in M2-like TAMs promotes mesenchymal-like states of glioma stem cells by modulating TGFβ2 secretion, which activates TGFβR/SMAD2/3 signaling in GSCs. TREM1 expression in TAMs is transcriptionally regulated by HIF-1α under hypoxic conditions and promotes immunosuppressive TAM polarization via the TLR2/AKT/mTOR/c-MYC axis.","method":"HIF-1α ChIP; TREM1 overexpression and knockdown in TAMs; TGFβ2 neutralization; SMAD2/3 Western blot; co-culture of TAMs and GSCs; TLR2/AKT/mTOR pathway inhibitors","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptional regulation established by ChIP, downstream TGFβ2/SMAD pathway by co-culture and pathway inhibitors; single lab, multiple orthogonal methods","pmids":["38479552"],"is_preprint":false},{"year":2010,"finding":"TREM-1 expression in macrophages in response to LPS and Pseudomonas aeruginosa is inhibited by prostaglandins PGD2, PGJ2, and 15-dPGJ2. This inhibition is independent of PGD2 receptors and PPARγ, but occurs through activation of Nrf2 and inhibition of NF-κB.","method":"Macrophage cell line treated with prostaglandins; PGD2 receptor antagonists; PPARγ antagonist/agonist; Nrf2 activation assay; NF-κB inhibition assay; TREM-1 expression by Western blot and flow cytometry","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection of pathway with receptor antagonists and transcription factor assays; single lab, multiple orthogonal approaches","pmids":["20797396"],"is_preprint":false},{"year":2013,"finding":"TREM-1 is crucial for macrophage polarization toward M1 phenotype. Kidney lysates from nephritic kidneys triggered TREM-1-dependent M1 polarization ex vivo. GM-CSF-derived M1 macrophages express higher levels of TREM-1 than M-CSF-derived cells. TREM-1 cross-linking strengthens induction of iNOS and GM-CSF in M1 macrophages.","method":"Ex vivo macrophage stimulation with nephritic kidney lysates; Trem-1 blocking antibody; ureteral obstruction mouse model; TREM-1 agonistic cross-linking; Western blot; flow cytometry; histology","journal":"Kidney international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ex vivo functional assay plus in vivo model with blocking and agonistic experiments; single lab","pmids":["24918157"],"is_preprint":false},{"year":2019,"finding":"Rheumatoid arthritis synovial fibroblasts (RASF) promote TREM-1 expression in CD14+ monocytes via COX-2/PGE2/EP2,4 signaling. Soluble factors (not direct cell contact) mediate this effect, as shown by transwell assay. COX-2 inhibitors, COX-2 siRNA, and EP1-4 antagonists each abrogated RASF-promoted TREM-1 upregulation in monocytes.","method":"RASF-monocyte co-culture; transwell assay; COX-2 siRNA; COX-2 inhibitors; EP1-4 antagonists; PGE2 ELISA; TREM-1 flow cytometry","journal":"Arthritis research & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transwell assay establishing soluble mediator requirement plus multiple pharmacological and genetic interventions targeting COX-2/PGE2/EP axis; single lab","pmids":["31287012"],"is_preprint":false},{"year":2019,"finding":"TREM-1 activation alleviates hyperoxia-induced lung injury in neonatal mice through downregulating RIPK3-mediated necroptosis and NLRP3 inflammasome activation. TREM-1 siRNA or Trem1 gene deletion enhanced lung inflammation and mortality under hyperoxia. Agonistic TREM-1 antibody treatment decreased lung inflammation, improved alveolarization, and diminished RIPK3 expression.","method":"Trem1 siRNA; Trem1 KO mice; agonistic TREM-1 antibody; neonatal hyperoxia model; Western blot for RIPK3, NLRP3; histology; survival analysis","journal":"American journal of respiratory cell and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO and gain-of-function (agonist antibody) with mechanistic pathway readouts; single lab","pmids":["30281332"],"is_preprint":false},{"year":2016,"finding":"LXR, RXR, RAR, and VDR nuclear receptor ligands induce TREM-1 expression on dendritic cells. TREM-1 triggering induced by retinoids increased TNFα and IL-1β release, establishing an active inflammatory role for NRL-activated TREM-1+ DCs.","method":"Transcriptomic profiling of DCs treated with 22R-HC; TREM-1 protein expression assay; cytokine ELISA after TREM-1 triggering; RXR/RAR/VDR ligand treatment; Trem-1 bone marrow chimera mouse tumor model","journal":"Oncoimmunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptomics plus functional cytokine assays plus in vivo tumor model; single lab, multiple approaches","pmids":["30723587"],"is_preprint":false},{"year":2023,"finding":"TREM1 agonism via afucosylated humanized anti-TREM1 antibody (PY159, with enhanced FcγR binding) induces TREM1 signaling leading to upregulation of costimulatory molecules on monocytes/macrophages, production of pro-inflammatory cytokines and chemokines, and enhancement of T cell activation in vitro. Anti-mouse TREM1 antibody PY159m promoted antitumor efficacy in syngeneic tumor models.","method":"Anti-TREM1 agonist antibody (PY159); cytokine/chemokine measurement; costimulatory molecule expression by flow cytometry; T cell activation assay; syngeneic mouse tumor models","journal":"Science translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — agonist antibody with multiple in vitro and in vivo functional readouts; single lab","pmids":["37647386"],"is_preprint":false},{"year":2016,"finding":"LPS induces TREM-1-dependent HIF-1α expression in human HaCaT keratinocytes via the PI3K/Akt pathway. TREM-1 siRNA silencing suppressed LPS-induced PI3K/Akt phosphorylation and HIF-1α expression. PI3K inhibitor wortmannin blocked HIF-1α induction without affecting TREM-1 expression itself, placing TREM-1 upstream of PI3K/Akt/HIF-1α.","method":"TREM-1 siRNA; PI3K inhibitor wortmannin; LPS-stimulated HaCaT keratinocytes; Western blot for pAkt, HIF-1α, TREM-1; immunofluorescence","journal":"Cell biology international","confidence":"Low","confidence_rationale":"Tier 3 / Weak — siRNA and pharmacological inhibitor in a single cell line with one lab; no genetic KO or in vivo validation","pmids":["27743451"],"is_preprint":false}],"current_model":"TREM-1 is a cell surface immunoreceptor expressed on myeloid cells that constitutively associates with the ITAM-bearing adapter DAP12; upon activation by multimerization/ligand clustering, TREM-1 signals through DAP12 phosphorylation, SYK, PI3K/AKT, p38MAPK, and ERK to amplify TLR-initiated pro-inflammatory responses including NF-κB, NLRP3 inflammasome/pyroptosis, ER stress (IRE-1α/XBP-1s), and metabolic reprogramming (mTOR/HIF-1α/glycolysis), while also regulating macrophage M1 polarization, neutrophil chemotaxis via NOX2-dependent superoxide, microglial phagocytosis of amyloid-β, mitochondrial integrity, and cell death pathways (necroptosis via mTOR/DRP1/RIPK3 and ferroptosis via PERK) across multiple tissue and disease contexts."},"narrative":{"mechanistic_narrative":"TREM-1 is a myeloid cell-surface immunoreceptor that amplifies innate inflammatory responses by partnering with the ITAM-bearing adapter DAP12, which it constitutively associates with and requires to transduce signals driving cytokine and chemokine production, reactive oxygen species generation, degranulation and phagocytosis [PMID:18192027, PMID:23108097]. Receptor activation is triggered by ligand-induced clustering: the TREM-1 ectodomain homooligomerizes in a concentration-dependent manner, DAP12 stabilizes surface expression and multimerization, and the degree of aggregation scales with Ca2+ flux, ROS, and cytokine output [PMID:29568119]. Downstream of DAP12, TREM-1 recruits SYK and signals through PI3K/AKT, PLC, p38MAPK and ERK to amplify inflammation, frequently in physical and functional cooperation with the TLR4/LPS receptor complex with which it co-localizes [PMID:20375613, PMID:21393102, PMID:31324751, PMID:32899943]. Through these axes TREM-1 converges on NF-κB and the NLRP3/caspase-1 inflammasome, and engages metabolic reprogramming via PI3K/AKT/mTOR-driven HIF-1α accumulation and glycolysis to license inflammasome activation and M1 macrophage polarization [PMID:36594089, PMID:34719965, PMID:38177990]. TREM-1 also couples to multiple regulated cell-death programs, including GSDMD-dependent pyroptosis, mTOR/DRP1/RIPK3-dependent necroptosis, and PERK-ER-stress-dependent ferroptosis [PMID:31324751, PMID:36879273, PMID:39461708]. Across disease models, genetic deletion or peptide blockade (LR12, LP17) of TREM-1 attenuates pathology in myocardial infarction, atherosclerosis, abdominal aortic aneurysm, liver fibrosis, stroke, and Alzheimer's disease, where it additionally governs microglial bioenergetics and amyloid-β handling [PMID:25840803, PMID:28007141, PMID:27762264, PMID:30137027, PMID:31263278, PMID:33258804, PMID:38539014, PMID:27670763]. Soluble TREM-1 is released into plasma during acute inflammatory injury [PMID:25840803].","teleology":[{"year":2007,"claim":"Established the core signaling architecture: how a receptor lacking intrinsic signaling motifs transduces activation into inflammatory output.","evidence":"Biochemical and functional assays in monocytes and neutrophils showing constitutive TREM-1/DAP12 association and DAP12 phosphorylation-dependent effector functions","pmids":["18192027","23108097"],"confidence":"High","gaps":["Endogenous physiological ligand not identified","Stoichiometry of the TREM-1/DAP12 complex not resolved"]},{"year":2007,"claim":"Provided early evidence for a cellular TREM-1 ligand, addressing what physically engages the receptor to amplify neutrophil responses.","evidence":"Recombinant TREM-1 fusion protein binding to platelets and TREM-1 blockade in platelet/PMN co-culture","pmids":["17452516"],"confidence":"Medium","gaps":["Molecular identity of the platelet ligand not defined","Single lab; binding shown only with a fusion protein"]},{"year":2009,"claim":"Defined the proximal kinase requirements for TREM-1-induced oxidative burst and its synergy with TLR4.","evidence":"Pharmacological inhibitors of PI3K/PLC/p38MAPK and Western blot of AKT/ERK phosphorylation in human PMN","pmids":["20375613"],"confidence":"Medium","gaps":["Inhibitor-based; direct kinase substrates not mapped","Relative ordering of PI3K, PLC and MAPK arms unresolved"]},{"year":2011,"claim":"Showed TREM-1 is physically and functionally integrated with the TLR4 receptor complex, explaining its amplification of LPS responses.","evidence":"Reciprocal blocking antibodies and co-localization immunofluorescence in human neutrophils","pmids":["21393102"],"confidence":"Medium","gaps":["Co-localization does not prove direct binary interaction","Single lab, primary cells only"]},{"year":2015,"claim":"Established TREM-1 as a causal driver of inflammatory tissue injury in vivo, moving beyond correlation in cardiac disease.","evidence":"Trem-1 knockout plus LR12 pharmacological inhibition in myocardial infarction models with imaging and functional readouts","pmids":["25840803"],"confidence":"High","gaps":["Cell type responsible (neutrophil vs monocyte) not isolated","Trigger for TREM-1 upregulation in ischemic myocardium undefined"]},{"year":2016,"claim":"Defined a pro-atherogenic role and a concrete mechanism via CD36 upregulation and foam-cell formation.","evidence":"Two independent Trem1/Apoe double-KO models, bone marrow chimeras, and LR12 blockade with histology and gene expression","pmids":["28007141","27762264"],"confidence":"High","gaps":["Direct link between TREM-1 signaling and CD36 transcription not mapped","Dyslipidemic serum factors that synergize with TREM-1 not identified"]},{"year":2016,"claim":"Revealed a beneficial, phagocytic role in CNS by showing TREM1 drives microglial clearance of amyloid-β.","evidence":"Trem1 knockdown/overexpression and agonist antibody in primary microglia and APP/PSEN1 mice with behavioral testing","pmids":["27670763"],"confidence":"High","gaps":["Reconciliation with later detrimental microglial roles unresolved","Receptor coupling to phagocytic machinery not detailed"]},{"year":2018,"claim":"Resolved the activation mechanism: TREM-1 is switched on by ectodomain oligomerization/clustering rather than monomeric ligation.","evidence":"Native mass spectrometry of ectodomain plus Ca2+/ROS/cytokine assays in monocytes and neutrophils; LR12 limits multimerization","pmids":["29568119"],"confidence":"High","gaps":["Atomic structure of the oligomer not solved","Endogenous clustering ligand still unknown"]},{"year":2018,"claim":"Demonstrated a cell-autonomous Kupffer cell role for TREM-1 in liver injury and stellate cell activation.","evidence":"Trem1 KO with Kupffer cell reconstitution in CCl4 chronic liver injury model","pmids":["30137027"],"confidence":"High","gaps":["Direct signal from Kupffer cells to stellate cells not defined"]},{"year":2018,"claim":"Linked TREM-1 to autophagy and ER stress (UPR) regulation in intestinal inflammation.","evidence":"LR12 and Trem-1 KO in DSS colitis with Western blots of autophagy/UPR markers and microbiota sequencing","pmids":["28961797"],"confidence":"Medium","gaps":["Causal direction between UPR markers and inflammation correlative","Single lab, marker-level readouts"]},{"year":2019,"claim":"Identified SYK as a direct interactor coupling TREM-1 to CARD9/NF-κB and NLRP3/GSDMD-driven pyroptosis in microglia.","evidence":"Co-IP of TREM-1/SYK plus pathway Western blots in MCAO model and microglial cultures with LP17 inhibition","pmids":["31324751"],"confidence":"Medium","gaps":["Co-IP without reciprocal/structural validation","Whether SYK binding is DAP12-mediated not shown"]},{"year":2019,"claim":"Established a gut-brain inflammatory axis whereby stroke-induced intestinal TREM1 drives barrier breakdown and bacterial translocation.","evidence":"Genetic KO, pharmacological inhibition, and anti-TREM1 PET imaging in MCAO stroke model","pmids":["31263278"],"confidence":"High","gaps":["Signal inducing intestinal TREM1 beyond noradrenergic input incomplete"]},{"year":2019,"claim":"Showed a context-dependent pro-survival role: TREM1 maintains mitochondrial integrity to protect HIV-infected macrophages from apoptosis.","evidence":"TREM1 siRNA in HIV-infected macrophages with BCL2-family Western blots, membrane potential, cytochrome c and caspase-9 readouts","pmids":["31719184"],"confidence":"High","gaps":["How TREM1 controls BCL2-family balance mechanistically unclear","siRNA only; no in vivo confirmation"]},{"year":2019,"claim":"Defined a mechanism for TREM-1 control of neutrophil chemotaxis via AKT-driven NOX2 superoxide production.","evidence":"Trem1 KO neutrophils with EPR superoxide measurement, oxygen consumption, migration assays and AKT Western blot","pmids":["30667543"],"confidence":"High","gaps":["Direct link between NOX2 superoxide and directional migration not fully separated from AKT"]},{"year":2019,"claim":"Connected TREM-1 to NET formation through eCIRP-induced ICAM-1+ neutrophils and Rho GTPase activation.","evidence":"TREM-1 KO and LP17 with rmCIRP, flow cytometry, Rho activation and NET quantification","pmids":["32506691"],"confidence":"Medium","gaps":["Whether eCIRP binds TREM-1 directly not established","Single lab"]},{"year":2020,"claim":"Showed TREM-1 activation induces ER stress via the IRE-1α/XBP-1s arm to amplify cytokine production.","evidence":"Agonist antibody plus IRE-1α inhibitor and XBP-1 silencing in macrophages and LPS-ALI model","pmids":["33957479"],"confidence":"Medium","gaps":["Mechanism linking surface receptor to UPR sensors unknown","Single lab"]},{"year":2020,"claim":"Identified WARS1 as an upstream inducer of TREM-1 acting through TLR2/TLR4-MyD88/TRIF, and confirmed the DAP12-SYK-AKT signaling loop.","evidence":"TLR/MyD88/TRIF KO cells, TREM-1 knockdown and SYK inhibitor with phosphoprotein Western blots","pmids":["32899943"],"confidence":"Medium","gaps":["Whether WARS1 acts as a TREM-1 ligand or only an inducer unclear"]},{"year":2020,"claim":"Demonstrated TREM-1 drives microglial pyroptosis through NLRP3 inflammasome activation after subarachnoid hemorrhage.","evidence":"Recombinant TREM-1 and LP17 antagonist in SAH model with GSDMD-N/IL-1β Western blots","pmids":["32862402"],"confidence":"Medium","gaps":["Pharmacological-only manipulation; no genetic KO","Single lab"]},{"year":2021,"claim":"Showed TREM-1 orchestrates AngII-driven Ly6Chi monocyte trafficking and aneurysm formation via CD62L upregulation.","evidence":"Apoe-/-Trem1-/- mice, LR12 blockade and agonist antibody in AngII-AAA model","pmids":["33258804"],"confidence":"High","gaps":["Direct link between AT1R and TREM-1 activation undefined"]},{"year":2021,"claim":"Placed TREM-1 on the STAT3/HIF-1α axis governing M1 versus M2 macrophage polarization.","evidence":"Trem1 knockdown/overexpression in RAW264.7, Trem1 KO mice and RNA-seq in periodontitis lesions","pmids":["34719965"],"confidence":"Medium","gaps":["Direct TREM-1 to STAT3 coupling not demonstrated"]},{"year":2021,"claim":"Identified a TREM-1 role in leukemic transformation, acting downstream or parallel to the DNA damage response in Fanconi anemia pre-LSCs.","evidence":"Trem1 shRNA in Fanca-/- pre-LSCs with transplantation and survival analysis","pmids":["27568523"],"confidence":"Medium","gaps":["Effector pathway driving pre-LSC expansion unidentified","shRNA knockdown only"]},{"year":2022,"claim":"Established metabolic reprogramming as the link between TREM-1 and inflammasome activation via PI3K/AKT/mTOR-HIF-1α-glycolysis.","evidence":"Agonist antibody with mTOR, HIF-1α and glycolysis (2-DG) inhibitors plus glucose consumption assays in LPS-ALI model","pmids":["36594089"],"confidence":"Medium","gaps":["Inhibitor-based; direct metabolic flux mapping limited"]},{"year":2022,"claim":"Implicated TREM-1 in cardiomyocyte pyroptosis through a SMC4/NEMO-NLRP3 axis in sepsis.","evidence":"Co-IP of TREM-1/SMC4 and siRNA in HL-1 cells with LR12 in CLP sepsis model","pmids":["36181338"],"confidence":"Medium","gaps":["Co-IP without reciprocal validation","How a myeloid receptor functions in cardiomyocytes unclear"]},{"year":2022,"claim":"Extended TREM-1 function beyond immune cells, showing it drives alveolar epithelial cell senescence in pulmonary fibrosis.","evidence":"Agonist antibody and LR12 in MLE12 cells and bleomycin model with senescence-marker Western blots","pmids":["36330909"],"confidence":"Medium","gaps":["Mechanism of epithelial TREM-1 expression and signaling undefined"]},{"year":2022,"claim":"Defined endothelial TREM-1 signaling through SYK/β-catenin controlling blood-brain barrier junction proteins after hemorrhage.","evidence":"LP17, SYK-activation CRISPR and SYK inhibitor R406 in ICH model with junction-protein Western blots","pmids":["37170484"],"confidence":"Medium","gaps":["Connection between SYK and β-catenin not mechanistically detailed"]},{"year":2022,"claim":"Extended the eCIRP-TREM-1 axis to renal endothelial cells driving acute kidney injury.","evidence":"TREM-1 KO and M3 inhibitory peptide with rmCIRP in mice and human renal endothelial cells","pmids":["36246143"],"confidence":"Medium","gaps":["Direct eCIRP-TREM-1 binding not shown","Single lab"]},{"year":2023,"claim":"Linked TREM-1 to macrophage necroptosis via mTOR-dependent DRP1 phosphorylation and RIPK3.","evidence":"Agonist antibody with rapamycin, Mdivi-1 and GSK872 in macrophages and LPS-ALI model; DRP1Ser616 Western blots","pmids":["36879273"],"confidence":"Medium","gaps":["Inhibitor-based; how TREM-1 engages mTOR-DRP1 directly unknown"]},{"year":2023,"claim":"Connected lipid droplet accumulation to TREM1 buildup, impaired lipophagy, and NLRP3-driven neuroinflammation in diabetic microglia.","evidence":"Co-IP/co-localization of LDs and TREM1 with LP17 in db/db and HFD/STZ models","pmids":["37204119"],"confidence":"Medium","gaps":["Nature of LD-TREM1 association not defined","Pharmacological-only manipulation"]},{"year":2023,"claim":"Showed TREM1 promotes gastric cancer progression by driving NET-mediated M2 macrophage polarization.","evidence":"TREM1 KO/knock-in mice with DNase-1 epistasis in MNNG-induced gastric cancer model","pmids":["38151453"],"confidence":"Medium","gaps":["Signal linking TREM1 to NET induction in tumors undefined"]},{"year":2023,"claim":"Defined an upstream regulatory cascade in which HIV Tat induces microglial TREM1 via TLR4/TICAM1/COX-2/PGE2.","evidence":"TREM1 siRNA with TLR4 blocking and COX-2/PGE2 inhibitors in HIV-infected human microglia","pmids":["37326481"],"confidence":"Medium","gaps":["Whether silencing-induced death reflects loss of survival signaling unclear"]},{"year":2023,"claim":"Provided therapeutic proof-of-concept that TREM1 agonism reprograms myeloid cells and drives antitumor immunity.","evidence":"Afucosylated anti-TREM1 agonist antibody (PY159) with cytokine, costimulation and T-cell assays plus syngeneic tumor models","pmids":["37647386"],"confidence":"Medium","gaps":["Mechanism distinguishing beneficial vs pathogenic TREM1 activation context-dependent"]},{"year":2024,"claim":"Established that TREM1 governs age- and amyloid-dependent microglial metabolism and cognitive decline, validated in human AD brain.","evidence":"Trem1 KO and haploinsufficiency in 5XFAD and APPSwe mice with metabolomics, bioenergetics, transcriptomics, PET and postmortem IHC","pmids":["38539014"],"confidence":"High","gaps":["Reconciliation with the earlier phagocytosis-promoting role in AD unresolved"]},{"year":2024,"claim":"Reinforced TREM1 control of M1 polarization and NF-κB-dependent NLRP3 activation in microglia in chronic migraine.","evidence":"TREM1 knockdown/overexpression with NF-κB inhibitor PDTC in BV2 cells and NTG migraine model with LR12","pmids":["38177990"],"confidence":"Medium","gaps":["Direct receptor-to-NF-κB coupling not isolated"]},{"year":2024,"claim":"Showed hypoxia/HIF-1α-induced TREM1 in glioblastoma TAMs promotes glioma stem cell mesenchymal states via TGFβ2/SMAD signaling.","evidence":"HIF-1α ChIP, TREM1 overexpression/knockdown, TGFβ2 neutralization and TAM/GSC co-culture","pmids":["38479552"],"confidence":"Medium","gaps":["TLR2/AKT/mTOR/c-MYC axis mechanistic links partly inferred"]},{"year":2024,"claim":"Linked TREM1 to microglial ferroptosis through the PERK arm of ER stress in diabetic cognitive impairment.","evidence":"LP17 and PERK inhibitor GSK2606414 in high-glucose BV2/HMC3 cells and HFD/STZ mice with iron and lipid peroxidation readouts","pmids":["39461708"],"confidence":"Medium","gaps":["Pharmacological-only; how TREM1 activates PERK unknown"]},{"year":null,"claim":"The endogenous physiological ligand(s) that cluster TREM-1 to initiate signaling, and the structural basis of how oligomerization is relayed through DAP12 to SYK across diverse cell types and opposing (pro-survival vs cell-death) outcomes, remain undefined.","evidence":"","pmids":[],"confidence":"High","gaps":["No definitive endogenous agonist ligand identified","No atomic-resolution structure of the activated TREM-1/DAP12 oligomer","Determinants of context-dependent beneficial vs pathogenic outcomes unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,8]},{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[7]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[1]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,8]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,18,40]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,11,24]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[11,27,33]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[17,10,24]}],"complexes":["TREM-1/DAP12 receptor complex","TLR4/LPS receptor complex"],"partners":["TYROBP","SYK","TLR4","SMC4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NP99","full_name":"Triggering receptor expressed on myeloid cells 1","aliases":["Triggering receptor expressed on monocytes 1"],"length_aa":234,"mass_kda":26.4,"function":"Cell surface receptor that plays important roles in innate and adaptive immunity by amplifying inflammatory responses (PubMed:10799849, PubMed:21393102). Upon activation by various ligands such as PGLYRP1, HMGB1 or HSP70, multimerizes and forms a complex with transmembrane adapter TYROBP/DAP12 (PubMed:17568691, PubMed:25595774, PubMed:29568119). In turn, initiates a SYK-mediated cascade of tyrosine phosphorylation, activating multiple downstream mediators such as BTK, MAPK1, MAPK3 or phospholipase C-gamma (PubMed:14656437, PubMed:21659545). This cascade promotes the neutrophil- and macrophage-mediated release of pro-inflammatory cytokines and/or chemokines, as well as their migration and thereby amplifies inflammatory responses that are triggered by bacterial and fungal infections (PubMed:17098818, PubMed:17568691). By also promoting the amplification of inflammatory signals that are initially triggered by Toll-like receptor (TLR) and NOD-like receptor engagement, plays a major role in the pathophysiology of acute and chronic inflammatory diseases of different etiologies including septic shock and atherosclerosis (PubMed:11323674, PubMed:21393102) Acts as a decoy receptor, counterbalancing TREM1 pro-inflammatory activity through the neutralization of its ligand","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q9NP99/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TREM1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TREM1","total_profiled":1310},"omim":[{"mim_id":"609716","title":"TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-LIKE PROTEIN 3; TREML3","url":"https://www.omim.org/entry/609716"},{"mim_id":"609715","title":"TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-LIKE PROTEIN 2; TREML2","url":"https://www.omim.org/entry/609715"},{"mim_id":"609714","title":"TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-LIKE PROTEIN 1; TREML1","url":"https://www.omim.org/entry/609714"},{"mim_id":"605086","title":"TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; TREM2","url":"https://www.omim.org/entry/605086"},{"mim_id":"605085","title":"TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TREM1","url":"https://www.omim.org/entry/605085"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":90.7},{"tissue":"lung","ntpm":61.6},{"tissue":"lymphoid tissue","ntpm":41.6}],"url":"https://www.proteinatlas.org/search/TREM1"},"hgnc":{"alias_symbol":["TREM-1","CD354"],"prev_symbol":[]},"alphafold":{"accession":"Q9NP99","domains":[{"cath_id":"2.60.40.10","chopping":"26-135","consensus_level":"high","plddt":91.2307,"start":26,"end":135}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NP99","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NP99-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NP99-F1-predicted_aligned_error_v6.png","plddt_mean":71.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TREM1","jax_strain_url":"https://www.jax.org/strain/search?query=TREM1"},"sequence":{"accession":"Q9NP99","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NP99.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NP99/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NP99"}},"corpus_meta":[{"pmid":"31324751","id":"PMC_31324751","title":"Microglial TREM-1 receptor mediates neuroinflammatory injury via interaction with SYK in experimental ischemic stroke.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31324751","citation_count":219,"is_preprint":false},{"pmid":"28245991","id":"PMC_28245991","title":"TREM-1 and its potential ligands in non-infectious diseases: from biology to clinical perspectives.","date":"2017","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/28245991","citation_count":202,"is_preprint":false},{"pmid":"23108097","id":"PMC_23108097","title":"TREM-1: intracellular signaling pathways and interaction with pattern recognition receptors.","date":"2012","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/23108097","citation_count":189,"is_preprint":false},{"pmid":"32862402","id":"PMC_32862402","title":"TREM-1 Exacerbates Neuroinflammatory Injury via NLRP3 Inflammasome-Mediated Pyroptosis in Experimental Subarachnoid Hemorrhage.","date":"2020","source":"Translational stroke research","url":"https://pubmed.ncbi.nlm.nih.gov/32862402","citation_count":178,"is_preprint":false},{"pmid":"18926286","id":"PMC_18926286","title":"From expression to signaling: roles of TREM-1 and TREM-2 in innate immunity and bacterial infection.","date":"2008","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/18926286","citation_count":174,"is_preprint":false},{"pmid":"17452516","id":"PMC_17452516","title":"TREM-1 ligand expression on platelets enhances neutrophil activation.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17452516","citation_count":174,"is_preprint":false},{"pmid":"37204119","id":"PMC_37204119","title":"Impaired lipophagy induced-microglial lipid droplets accumulation contributes to the buildup of TREM1 in diabetes-associated cognitive impairment.","date":"2023","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/37204119","citation_count":169,"is_preprint":false},{"pmid":"18192027","id":"PMC_18192027","title":"The TREM-1/DAP12 pathway.","date":"2007","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/18192027","citation_count":169,"is_preprint":false},{"pmid":"31263278","id":"PMC_31263278","title":"Peripheral TREM1 responses to brain and intestinal immunogens amplify stroke severity.","date":"2019","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31263278","citation_count":138,"is_preprint":false},{"pmid":"30685385","id":"PMC_30685385","title":"Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease.","date":"2019","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/30685385","citation_count":138,"is_preprint":false},{"pmid":"36594089","id":"PMC_36594089","title":"TREM-1 governs NLRP3 inflammasome activation of macrophages by firing up glycolysis in acute lung injury.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36594089","citation_count":131,"is_preprint":false},{"pmid":"18096709","id":"PMC_18096709","title":"TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer.","date":"2007","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18096709","citation_count":123,"is_preprint":false},{"pmid":"25840803","id":"PMC_25840803","title":"TREM-1 Mediates Inflammatory Injury and Cardiac Remodeling Following Myocardial Infarction.","date":"2015","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/25840803","citation_count":118,"is_preprint":false},{"pmid":"32908142","id":"PMC_32908142","title":"Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32908142","citation_count":97,"is_preprint":false},{"pmid":"25505454","id":"PMC_25505454","title":"Triggering receptor expressed on myeloid cells-1 (TREM-1): a new player in antiviral immunity?","date":"2014","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/25505454","citation_count":96,"is_preprint":false},{"pmid":"28007141","id":"PMC_28007141","title":"Genetic and Pharmacological Inhibition of TREM-1 Limits the Development of Experimental Atherosclerosis.","date":"2016","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/28007141","citation_count":91,"is_preprint":false},{"pmid":"27762264","id":"PMC_27762264","title":"TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27762264","citation_count":88,"is_preprint":false},{"pmid":"35132073","id":"PMC_35132073","title":"Single-cell RNA sequencing identifies an Il1rn+/Trem1+ macrophage subpopulation as a cellular target for mitigating the progression of thoracic aortic aneurysm and dissection.","date":"2022","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35132073","citation_count":86,"is_preprint":false},{"pmid":"30137027","id":"PMC_30137027","title":"The innate immune receptor TREM-1 promotes liver injury and fibrosis.","date":"2018","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/30137027","citation_count":83,"is_preprint":false},{"pmid":"29568119","id":"PMC_29568119","title":"TREM-1 multimerization is essential for its activation on monocytes and neutrophils.","date":"2018","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29568119","citation_count":81,"is_preprint":false},{"pmid":"27670763","id":"PMC_27670763","title":"TREM1 facilitates microglial phagocytosis of amyloid beta.","date":"2016","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/27670763","citation_count":76,"is_preprint":false},{"pmid":"33258804","id":"PMC_33258804","title":"TREM-1 orchestrates angiotensin II-induced monocyte trafficking and promotes experimental abdominal aortic aneurysm.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/33258804","citation_count":74,"is_preprint":false},{"pmid":"28961797","id":"PMC_28961797","title":"TREM-1 Inhibition Restores Impaired Autophagy Activity and Reduces Colitis in Mice.","date":"2018","source":"Journal of Crohn's & colitis","url":"https://pubmed.ncbi.nlm.nih.gov/28961797","citation_count":71,"is_preprint":false},{"pmid":"38177990","id":"PMC_38177990","title":"Microglia TREM1-mediated neuroinflammation contributes to central sensitization via the NF-κB pathway in a chronic migraine model.","date":"2024","source":"The journal of headache and pain","url":"https://pubmed.ncbi.nlm.nih.gov/38177990","citation_count":63,"is_preprint":false},{"pmid":"33297569","id":"PMC_33297569","title":"Function of TREM1 and TREM2 in Liver-Related Diseases.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33297569","citation_count":60,"is_preprint":false},{"pmid":"37269870","id":"PMC_37269870","title":"Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial.","date":"2023","source":"The Lancet. Respiratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37269870","citation_count":60,"is_preprint":false},{"pmid":"21393102","id":"PMC_21393102","title":"TREM-1 interaction with the LPS/TLR4 receptor complex.","date":"2011","source":"European cytokine network","url":"https://pubmed.ncbi.nlm.nih.gov/21393102","citation_count":58,"is_preprint":false},{"pmid":"35784361","id":"PMC_35784361","title":"TREM-1 Modulation Strategies for Sepsis.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35784361","citation_count":57,"is_preprint":false},{"pmid":"32506691","id":"PMC_32506691","title":"Extracellular CIRP and TREM-1 axis promotes ICAM-1-Rho-mediated NETosis in sepsis.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32506691","citation_count":57,"is_preprint":false},{"pmid":"31719184","id":"PMC_31719184","title":"TREM-1 Protects HIV-1-Infected Macrophages from Apoptosis through Maintenance of Mitochondrial Function.","date":"2019","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/31719184","citation_count":56,"is_preprint":false},{"pmid":"24918157","id":"PMC_24918157","title":"TREM-1 regulates macrophage polarization in ureteral obstruction.","date":"2014","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/24918157","citation_count":55,"is_preprint":false},{"pmid":"36879273","id":"PMC_36879273","title":"TREM-1 triggers necroptosis of macrophages through mTOR-dependent mitochondrial fission during acute lung injury.","date":"2023","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36879273","citation_count":54,"is_preprint":false},{"pmid":"32736673","id":"PMC_32736673","title":"TREM-1-targeting LP17 attenuates cerebral ischemia-induced neuronal injury by inhibiting oxidative stress and pyroptosis.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32736673","citation_count":48,"is_preprint":false},{"pmid":"38749377","id":"PMC_38749377","title":"TREM1: Activation, signaling, cancer and therapy.","date":"2024","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/38749377","citation_count":47,"is_preprint":false},{"pmid":"29093489","id":"PMC_29093489","title":"TREM-1 promotes intestinal tumorigenesis.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29093489","citation_count":46,"is_preprint":false},{"pmid":"36068612","id":"PMC_36068612","title":"The associations between plasma soluble Trem1 and neurological diseases: a Mendelian randomization study.","date":"2022","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/36068612","citation_count":44,"is_preprint":false},{"pmid":"38539014","id":"PMC_38539014","title":"TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer disease mouse models.","date":"2024","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/38539014","citation_count":43,"is_preprint":false},{"pmid":"33390769","id":"PMC_33390769","title":"TREM-1 promoted apoptosis and inhibited autophagy in LPS-treated HK-2 cells through the NF-κB pathway.","date":"2021","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33390769","citation_count":43,"is_preprint":false},{"pmid":"23810411","id":"PMC_23810411","title":"TREM-1 inhibition attenuates inflammation and tumor within the colon.","date":"2013","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23810411","citation_count":42,"is_preprint":false},{"pmid":"37647386","id":"PMC_37647386","title":"TREM1 activation of myeloid cells promotes antitumor immunity.","date":"2023","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37647386","citation_count":41,"is_preprint":false},{"pmid":"27568730","id":"PMC_27568730","title":"Therapeutic Potential of Targeting TREM-1 in Inflammatory Diseases and Cancer.","date":"2016","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/27568730","citation_count":41,"is_preprint":false},{"pmid":"35856334","id":"PMC_35856334","title":"FOXM1 network in association with TREM1 suppression regulates NET formation in diabetic foot ulcers.","date":"2022","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/35856334","citation_count":41,"is_preprint":false},{"pmid":"31440123","id":"PMC_31440123","title":"Therapeutic Effect of Modulating TREM-1 via Anti-inflammation and Autophagy in Parkinson's Disease.","date":"2019","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31440123","citation_count":40,"is_preprint":false},{"pmid":"36273145","id":"PMC_36273145","title":"The role of triggering receptor expressed on myeloid cells-1 (TREM-1) in central nervous system diseases.","date":"2022","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/36273145","citation_count":39,"is_preprint":false},{"pmid":"15309732","id":"PMC_15309732","title":"Expression of TREM-1 mRNA in acute pancreatitis.","date":"2004","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/15309732","citation_count":39,"is_preprint":false},{"pmid":"29095622","id":"PMC_29095622","title":"Novel TREM-1 Inhibitors Attenuate Tumor Growth and Prolong Survival in Experimental Pancreatic Cancer.","date":"2017","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/29095622","citation_count":38,"is_preprint":false},{"pmid":"20375613","id":"PMC_20375613","title":"Signaling pathways of the TREM-1- and TLR4-mediated neutrophil oxidative burst.","date":"2009","source":"Journal of innate immunity","url":"https://pubmed.ncbi.nlm.nih.gov/20375613","citation_count":38,"is_preprint":false},{"pmid":"32326783","id":"PMC_32326783","title":"The role of the triggering receptor expressed on myeloid cells-1 (TREM-1) in non-bacterial infections.","date":"2020","source":"Critical reviews in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/32326783","citation_count":35,"is_preprint":false},{"pmid":"32899943","id":"PMC_32899943","title":"Tryptophanyl-tRNA Synthetase 1 Signals Activate TREM-1 via TLR2 and TLR4.","date":"2020","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/32899943","citation_count":34,"is_preprint":false},{"pmid":"29644420","id":"PMC_29644420","title":"Soluble TREM-1 as a predictive factor of neonatal sepsis: a meta-analysis.","date":"2018","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/29644420","citation_count":34,"is_preprint":false},{"pmid":"35223446","id":"PMC_35223446","title":"Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35223446","citation_count":34,"is_preprint":false},{"pmid":"34719965","id":"PMC_34719965","title":"Trem1 Induces Periodontal Inflammation via Regulating M1 Polarization.","date":"2021","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/34719965","citation_count":33,"is_preprint":false},{"pmid":"32379561","id":"PMC_32379561","title":"Triggering receptor expressed on myeloid cells-1 (TREM-1) as a therapeutic target in infectious and noninfectious disease: a critical review.","date":"2020","source":"International reviews of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32379561","citation_count":33,"is_preprint":false},{"pmid":"31013451","id":"PMC_31013451","title":"Regulation of PGLYRP1 and TREM-1 during Progression and Resolution of Gingival Inflammation.","date":"2019","source":"JDR clinical and translational research","url":"https://pubmed.ncbi.nlm.nih.gov/31013451","citation_count":32,"is_preprint":false},{"pmid":"30667543","id":"PMC_30667543","title":"TREM-1 regulates neutrophil chemotaxis by promoting NOX-dependent superoxide production.","date":"2019","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/30667543","citation_count":32,"is_preprint":false},{"pmid":"20797396","id":"PMC_20797396","title":"Expression of TREM-1 is inhibited by PGD2 and PGJ2 in macrophages.","date":"2010","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/20797396","citation_count":32,"is_preprint":false},{"pmid":"24012964","id":"PMC_24012964","title":"Regulation of TREM-1 expression by 1,25-dihydroxyvitamin D3 in human monocytes/macrophages.","date":"2013","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/24012964","citation_count":30,"is_preprint":false},{"pmid":"26650186","id":"PMC_26650186","title":"GPR84 and TREM-1 Signaling Contribute to the Pathogenesis of Reflux Esophagitis.","date":"2016","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/26650186","citation_count":29,"is_preprint":false},{"pmid":"31287012","id":"PMC_31287012","title":"Rheumatoid arthritis synovial fibroblasts promote TREM-1 expression in monocytes via COX-2/PGE2 pathway.","date":"2019","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31287012","citation_count":28,"is_preprint":false},{"pmid":"33537747","id":"PMC_33537747","title":"TREM-1+ Macrophages Define a Pathogenic Cell Subset in the Intestine of Crohn's Disease Patients.","date":"2021","source":"Journal of Crohn's & colitis","url":"https://pubmed.ncbi.nlm.nih.gov/33537747","citation_count":27,"is_preprint":false},{"pmid":"30205488","id":"PMC_30205488","title":"TREM-1; Is It a Pivotal Target for Cardiovascular Diseases?","date":"2018","source":"Journal of cardiovascular development and disease","url":"https://pubmed.ncbi.nlm.nih.gov/30205488","citation_count":26,"is_preprint":false},{"pmid":"30010135","id":"PMC_30010135","title":"TREM1 mRNA Expression in Leukocytes and Cognitive Function in Japanese Patients with Alzheimer's Disease.","date":"2018","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/30010135","citation_count":26,"is_preprint":false},{"pmid":"36691481","id":"PMC_36691481","title":"Acteoside alleviates UUO-induced inflammation and fibrosis by regulating the HMGN1/TLR4/TREM1 signaling pathway.","date":"2023","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/36691481","citation_count":25,"is_preprint":false},{"pmid":"33536478","id":"PMC_33536478","title":"Elevated serum TREM-1 is associated with periodontitis and disease activity in rheumatoid arthritis.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33536478","citation_count":25,"is_preprint":false},{"pmid":"35390422","id":"PMC_35390422","title":"Triggering receptor expressed on myeloid cells-1 (TREM-1) inhibition in atherosclerosis.","date":"2022","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/35390422","citation_count":24,"is_preprint":false},{"pmid":"30306456","id":"PMC_30306456","title":"Genes interconnecting AMPK and TREM-1 and associated microRNAs in rotator cuff tendon injury.","date":"2018","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30306456","citation_count":24,"is_preprint":false},{"pmid":"30281332","id":"PMC_30281332","title":"TREM-1 Attenuates RIPK3-mediated Necroptosis in Hyperoxia-induced Lung Injury in Neonatal Mice.","date":"2019","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30281332","citation_count":24,"is_preprint":false},{"pmid":"32684831","id":"PMC_32684831","title":"TREM-1 and TREM-2 Expression on Blood Monocytes Could Help Predict Survival in High-Grade Glioma Patients.","date":"2020","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/32684831","citation_count":23,"is_preprint":false},{"pmid":"38151453","id":"PMC_38151453","title":"TREM1 facilitates the development of gastric cancer through regulating neutrophil extracellular traps-mediated macrophage polarization.","date":"2023","source":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/38151453","citation_count":22,"is_preprint":false},{"pmid":"29615799","id":"PMC_29615799","title":"Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29615799","citation_count":22,"is_preprint":false},{"pmid":"34860175","id":"PMC_34860175","title":"TREM1 fosters an immunosuppressive tumor microenvironment in papillary thyroid cancer.","date":"2022","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34860175","citation_count":21,"is_preprint":false},{"pmid":"36181338","id":"PMC_36181338","title":"TREM-1 induces pyroptosis in cardiomyocytes by activating NLRP3 inflammasome through the SMC4/NEMO pathway.","date":"2022","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/36181338","citation_count":20,"is_preprint":false},{"pmid":"36330909","id":"PMC_36330909","title":"TREM-1 exacerbates bleomycin-induced pulmonary fibrosis by aggravating alveolar epithelial cell senescence in mice.","date":"2022","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36330909","citation_count":20,"is_preprint":false},{"pmid":"22611379","id":"PMC_22611379","title":"TREM-1 Promotes Pancreatitis-Associated Intestinal Barrier Dysfunction.","date":"2012","source":"Gastroenterology research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/22611379","citation_count":20,"is_preprint":false},{"pmid":"31268375","id":"PMC_31268375","title":"TREM1/Dap12-based CAR-T cells show potent antitumor activity.","date":"2019","source":"Immunotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/31268375","citation_count":20,"is_preprint":false},{"pmid":"34864782","id":"PMC_34864782","title":"Inhibition of the Interaction of TREM-1 and eCIRP Attenuates Inflammation and Improves Survival in Hepatic Ischemia/Reperfusion.","date":"2022","source":"Shock (Augusta, Ga.)","url":"https://pubmed.ncbi.nlm.nih.gov/34864782","citation_count":20,"is_preprint":false},{"pmid":"30805986","id":"PMC_30805986","title":"Inhibition of TREM-1 attenuates inflammation and lipid accumulation in diet-induced nonalcoholic fatty liver disease.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30805986","citation_count":20,"is_preprint":false},{"pmid":"36246143","id":"PMC_36246143","title":"Extracellular CIRP induces acute kidney injury via endothelial TREM-1.","date":"2022","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/36246143","citation_count":20,"is_preprint":false},{"pmid":"35187741","id":"PMC_35187741","title":"Circular RNA hsa_circ_0083756 promotes intervertebral disc degeneration by sponging miR-558 and regulating TREM1 expression.","date":"2022","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/35187741","citation_count":19,"is_preprint":false},{"pmid":"39094542","id":"PMC_39094542","title":"Osteoclast-derived exosomes influence osteoblast differentiation in osteoporosis progression via the lncRNA AW011738/ miR-24-2-5p/ TREM1 axis.","date":"2024","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/39094542","citation_count":18,"is_preprint":false},{"pmid":"35292178","id":"PMC_35292178","title":"A novel eCIRP/TREM-1 pathway inhibitor attenuates acute kidney injury.","date":"2022","source":"Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/35292178","citation_count":18,"is_preprint":false},{"pmid":"37170484","id":"PMC_37170484","title":"Endothelial TREM-1 receptor regulates the blood-brain barrier integrity after intracerebral hemorrhage in mice via SYK/β-catenin signaling.","date":"2023","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/37170484","citation_count":18,"is_preprint":false},{"pmid":"31365951","id":"PMC_31365951","title":"TREM-1 deficiency attenuates the inflammatory responses in LPS-induced murine endometritis.","date":"2019","source":"Microbial biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/31365951","citation_count":18,"is_preprint":false},{"pmid":"38479552","id":"PMC_38479552","title":"Hypoxia-induced TREM1 promotes mesenchymal-like states of glioma stem cells via alternatively activating tumor-associated macrophages.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38479552","citation_count":17,"is_preprint":false},{"pmid":"33522328","id":"PMC_33522328","title":"TREM-1 isoforms in bacterial infections: to immune modulation and beyond.","date":"2021","source":"Critical reviews in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/33522328","citation_count":16,"is_preprint":false},{"pmid":"27331093","id":"PMC_27331093","title":"Data on TREM-1 activation destabilizing carotid plaques.","date":"2016","source":"Data in brief","url":"https://pubmed.ncbi.nlm.nih.gov/27331093","citation_count":16,"is_preprint":false},{"pmid":"27743451","id":"PMC_27743451","title":"Lipopolysaccharide induces TREM-1-dependent HIF-1α expression in human keratinocyte cell line.","date":"2016","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/27743451","citation_count":16,"is_preprint":false},{"pmid":"27568523","id":"PMC_27568523","title":"The immune receptor Trem1 cooperates with diminished DNA damage response to induce preleukemic stem cell expansion.","date":"2016","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/27568523","citation_count":16,"is_preprint":false},{"pmid":"37405587","id":"PMC_37405587","title":"The orchestrating role of deteriorating neurons and TREM-1 in crosstalk with SYK in Alzheimer's disease progression and neuroinflammation.","date":"2023","source":"Inflammopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37405587","citation_count":16,"is_preprint":false},{"pmid":"30723587","id":"PMC_30723587","title":"Nuclear receptor ligands induce TREM-1 expression on dendritic cells: analysis of their role in tumors.","date":"2018","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/30723587","citation_count":16,"is_preprint":false},{"pmid":"39461708","id":"PMC_39461708","title":"TREM1 induces microglial ferroptosis through the PERK pathway in diabetic-associated cognitive impairment.","date":"2024","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/39461708","citation_count":15,"is_preprint":false},{"pmid":"37147138","id":"PMC_37147138","title":"Jo-1 Antibodies From Myositis Induce Complement-Dependent Cytotoxicity and TREM-1 Upregulation in Muscle Endothelial Cells.","date":"2023","source":"Neurology(R) neuroimmunology & neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/37147138","citation_count":15,"is_preprint":false},{"pmid":"33957479","id":"PMC_33957479","title":"Activation of TREM-1 induces endoplasmic reticulum stress through IRE-1α/XBP-1s pathway in murine macrophages.","date":"2021","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33957479","citation_count":15,"is_preprint":false},{"pmid":"38570153","id":"PMC_38570153","title":"Inhibition of TREM-1 alleviates neuroinflammation by modulating microglial polarization via SYK/p38MAPK signaling pathway after traumatic brain injury.","date":"2024","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/38570153","citation_count":15,"is_preprint":false},{"pmid":"37326481","id":"PMC_37326481","title":"HIV-1 Tat Upregulates TREM1 Expression in Human Microglia.","date":"2023","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/37326481","citation_count":14,"is_preprint":false},{"pmid":"38469682","id":"PMC_38469682","title":"TREM1/DAP12 based novel multiple chain CAR-T cells targeting DLL3 show robust anti-tumour efficacy for small cell lung cancer.","date":"2024","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38469682","citation_count":14,"is_preprint":false},{"pmid":"37848000","id":"PMC_37848000","title":"TREM-1, TREM-2 and their association with disease severity in patients with COVID-19.","date":"2023","source":"Annals of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37848000","citation_count":14,"is_preprint":false},{"pmid":"39384003","id":"PMC_39384003","title":"Inhibition of TREM-1 ameliorates angiotensin II-induced atrial fibrillation by attenuating macrophage infiltration and inflammation through the PI3K/AKT/FoxO3a signaling pathway.","date":"2024","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/39384003","citation_count":14,"is_preprint":false},{"pmid":"35637975","id":"PMC_35637975","title":"TREM-1 Modulates Dendritic Cells Maturation and Dendritic Cell-Mediated T-Cell Activation Induced by ox-LDL.","date":"2022","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/35637975","citation_count":14,"is_preprint":false},{"pmid":"34097504","id":"PMC_34097504","title":"Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) Contributes to Bordetella pertussis Inflammatory Pathology.","date":"2021","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/34097504","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55523,"output_tokens":12711,"usd":0.178617,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":24048,"output_tokens":8289,"usd":0.163733,"stage2_stop_reason":"end_turn"},"total_usd":0.34235,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"TREM-1 constitutively associates with DAP12, an ITAM-bearing adapter protein, which is required for induction of intracellular signaling downstream of TREM-1 in monocytes and neutrophils. DAP12 phosphorylation following TREM-1 activation leads to production of pro-inflammatory cytokines, chemokines, and reactive oxygen species, and triggers rapid degranulation and phagocytosis.\",\n      \"method\": \"Biochemical and functional assays in monocytes and neutrophils; review synthesizing prior experimental work\",\n      \"journal\": \"Immunology letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — constitutive TREM-1/DAP12 association replicated across multiple independent labs and studies; functional consequences (cytokine production, ROS, degranulation) established by multiple orthogonal approaches\",\n      \"pmids\": [\"18192027\", \"23108097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"A TREM-1 ligand is expressed on human platelets. Using a recombinant TREM-1 fusion protein, specific binding of TREM-1 to platelets was demonstrated. TREM-1/ligand interaction on platelets is required for platelet-induced augmentation of PMN effector functions (provoked by LPS), but not for platelet/PMN complex formation (which depends on integrins and selectins).\",\n      \"method\": \"Recombinant TREM-1 fusion protein binding assay; functional PMN activation assays with platelet co-culture; TREM-1 blocking\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding demonstrated with fusion protein, functional consequence shown with blocking; single lab, two orthogonal methods\",\n      \"pmids\": [\"17452516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TREM-1-induced oxidative burst in human PMN requires phosphatidyl inositide 3-kinase (PI3K), phospholipase C, and p38MAPK. Protein kinase B (AKT) and ERK show characteristic phosphorylation patterns upon TREM-1 or TLR4 single or co-ligation, indicating individual activation pathways that synergize.\",\n      \"method\": \"Pharmacological inhibitors of PI3K, PLC, p38MAPK; Western blot analysis of AKT and ERK phosphorylation; oxidative burst assay in human PMN\",\n      \"journal\": \"Journal of innate immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase/signaling assay with pharmacological inhibitors and Western blot, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"20375613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TREM-1 interacts with or is a component of the TLR4/LPS receptor complex in human neutrophils. Blocking anti-TREM-1 antibodies inhibited LPS-induced TNF-α production, and blocking TLR4 reduced the effects of TREM-1 cross-linking; co-localization of TREM-1 and TLR4 was observed.\",\n      \"method\": \"Blocking antibodies against TREM-1 and TLR4; TLR4-specific inhibitor; co-localization by immunofluorescence in human neutrophils; cytokine measurement\",\n      \"journal\": \"European cytokine network\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-localization plus reciprocal blocking experiments in primary human cells; single lab, two orthogonal approaches\",\n      \"pmids\": [\"21393102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TREM-1 expression is upregulated in ischemic myocardium after MI. Trem-1 genetic invalidation or pharmacological inhibition (LR12 peptide) dampens myocardial inflammation, limits neutrophil recruitment and MCP-1 production, reduces classical monocyte mobilization to the heart, improves left ventricular function and survival. Soluble TREM-1 (sTREM-1) is detectable in plasma of acute MI patients.\",\n      \"method\": \"Trem-1 knockout mice; pharmacological inhibition with LR12 peptide; FDG-PET imaging; conductance catheter studies; n=20-22 per group\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO plus pharmacological inhibition in multiple MI models with defined cellular and functional phenotypes; replicated across permanent and transient ischemia models\",\n      \"pmids\": [\"25840803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Trem-1 genetic invalidation in chimeric Ldlr-/- and ApoE-/-/Trem-1-/- mice reduces atherosclerotic plaque size and inflammation, alters monocyte recruitment into lesions, and inhibits TLR4-initiated macrophage responses. TREM-1 plays a critical role in upregulation of CD36, thereby promoting inflammatory foam cell formation. Pharmacological blockade with LR12 peptide similarly reduces atherosclerosis.\",\n      \"method\": \"Bone marrow chimera mice (Trem-1-/-); ApoE-/-Trem-1-/- double KO; LR12 pharmacological blockade; histology; flow cytometry; gene expression\",\n      \"journal\": \"Journal of the American College of Cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic invalidation replicated in two different KO models plus pharmacological blockade, with multiple orthogonal readouts; independently supported by a second study in the same year\",\n      \"pmids\": [\"28007141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TREM-1 is highly upregulated under dyslipidemic conditions on circulating and lesion-infiltrating myeloid cells. TREM-1 promotes atherosclerosis by synergizing with HFCD serum-derived factors to promote pro-inflammatory cytokine responses and foam cell formation, and by skewing monocyte differentiation and enhancing lipid accumulation. Trem1-/-/Apoe-/- mice exhibit substantially attenuated diet-induced atherogenesis.\",\n      \"method\": \"Trem1-/-/Apoe-/- double KO mice; human monocyte/macrophage culture with HFCD serum; cytokine assays; histology\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO model plus in vitro mechanistic studies; independent replication of TREM-1 pro-atherogenic role in a separate lab from PMID:28007141\",\n      \"pmids\": [\"27762264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TREM1 facilitates microglial phagocytosis of amyloid-β. Knockdown of Trem1 in mouse primary microglia decreased Aβ phagocytosis; overexpression or agonistic antibody activation increased phagocytosis and reduced Aβ burden. Trem1 knockdown in APP/PSEN1 mice increased Aβ1-42 levels and total amyloid burden; selective overexpression on microglia ameliorated Aβ neuropathology and rescued spatial cognitive impairments.\",\n      \"method\": \"Trem1 knockdown and overexpression in primary mouse microglia; in vivo AAV-mediated expression in APP/PSEN1 mice; agonistic TREM1 antibody; Aβ phagocytosis assays; spatial memory tests\",\n      \"journal\": \"Acta neuropathologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function and gain-of-function both in vitro and in vivo, multiple orthogonal methods including behavioral outcomes; single lab but comprehensive\",\n      \"pmids\": [\"27670763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TREM-1 is activated by multimerization/clustering at the cell surface. Levels of intracellular Ca2+ release, ROS, and cytokine production correlate with the degree of TREM-1 aggregation. LPS induces a two-step process in monocytes: upregulation then clustering of TREM-1; in neutrophils LPS induces rapid membrane reorganization of TREM-1. The ectodomain of TREM-1 homooligomerizes in a concentration-dependent manner. DAP12 stabilizes TREM-1 surface expression and multimerization. TREM-1 inhibitor LR12 limits TREM-1 multimerization, supporting ligand-induced, receptor-mediated dimerization.\",\n      \"method\": \"Native mass spectrometry; Ca2+ flux assays; ROS assays; cytokine ELISA; flow cytometry on primary human monocytes and neutrophils; TREM-1 ectodomain oligomerization in vitro\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of ectodomain oligomerization plus native MS, combined with cellular functional assays; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"29568119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TREM-1 promotes liver injury and fibrosis by intensifying hepatic inflammation. TREM-1 expression is limited to liver macrophages/monocytes and is upregulated on Kupffer cells in CCl4-induced chronic liver injury. TREM-1 signaling promotes pro-inflammatory cytokine production and inflammatory cell mobilization to injury sites. Reconstitution of Trem1-deficient mice with Trem1-sufficient Kupffer cells restored recruitment of inflammatory monocytes and severity of liver injury, establishing TREM-1 as a master regulator of Kupffer cell activation that activates hepatic stellate cells.\",\n      \"method\": \"Trem1 knockout mice; Kupffer cell reconstitution experiment; CCl4 chronic liver injury model; flow cytometry; histology; cytokine measurement\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO plus cell reconstitution experiment establishing cell-autonomous Kupffer cell role; multiple orthogonal methods\",\n      \"pmids\": [\"30137027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TREM-1 inhibition restores impaired autophagy activity (macroautophagy and CMA) and reduces ER stress (UPR) in colitis. TREM-1 inhibition (pharmacological LR12 or genetic KO) increased ATG1/ULK-1, ATG13, ATG5, ATG16L1, MAP1LC3-I/II, HSPA8, HSP90AA1 and decreased PERK, IRE-1α, ATF-6α expression in colitic mice. TREM-1 inhibition also prevented dysbiosis.\",\n      \"method\": \"LR12 pharmacological inhibition; Trem-1 KO mice; DSS colitis model; Western blotting for autophagy and UPR markers; MiSeq microbiota sequencing\",\n      \"journal\": \"Journal of Crohn's & colitis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and pharmacological inhibition with Western blot protein-level mechanistic readouts; single lab, two complementary approaches\",\n      \"pmids\": [\"28961797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TREM-1 interacts directly with spleen tyrosine kinase (SYK) in microglia. TREM-1 activates downstream pro-inflammatory pathways CARD9/NF-κB and NLRP3/caspase-1 through SYK interaction. TREM-1-induced SYK activation promotes microglial pyroptosis by elevating gasdermin D (GSDMD) and its N-terminal fragment (GSDMD-N), forming pores that release intracellular inflammatory factors.\",\n      \"method\": \"Co-immunoprecipitation (TREM-1/SYK interaction); Western blot for pathway components; in vivo MCAO mouse model and in vitro microglial cultures; LP17 pharmacological inhibition\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP demonstrated interaction, supported by in vivo and in vitro functional data; single lab\",\n      \"pmids\": [\"31324751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Peripheral CD11b+CD45+ myeloid TREM1 induction amplifies stroke injury via pro-inflammatory innate immune activation. Following stroke, noradrenergic-dependent increases in gut permeability induce TREM1 on Ly6C+MHCII+ intestinal lamina propria macrophages, further increasing epithelial permeability and facilitating bacterial translocation. Genetic or pharmacological TREM1 inhibition improved outcome via antioxidant and anti-inflammatory mechanisms.\",\n      \"method\": \"TREM1 genetic KO; pharmacological inhibition; PET imaging with radiolabeled anti-TREM1 antibody; trafficking studies; intestinal permeability assays in MCAO stroke model\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO plus pharmacological inhibition plus PET imaging; multiple orthogonal methods; published in high-impact journal\",\n      \"pmids\": [\"31263278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TREM1 protects HIV-1-infected macrophages from apoptosis through maintenance of mitochondrial function. Upon HIV infection, TREM1 expression increases along with BCL2, BCLXL, MFN1, MFN2 and BIM translocation to mitochondria. TREM1 silencing in HIV-infected macrophages decreased BCL2, BCLXL, MFN1, MFN2, increased BAD and BAX, causing disruption of mitochondrial membrane potential (Δψm), cytochrome c release, caspase 9 cleavage, and apoptosis. HIV Tat, gp120, and TLR8 agonist RNA40 recapitulate these effects.\",\n      \"method\": \"TREM1 siRNA silencing in HIV-infected macrophages; mitochondrial membrane potential assay; cytochrome c release; Western blot for BCL2 family proteins; apoptosis assays\",\n      \"journal\": \"mBio\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function (siRNA) with multiple mechanistic readouts (mitochondrial potential, cytochrome c, caspase cleavage, apoptosis) establishing pathway position; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"31719184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TREM-1 regulates neutrophil chemotaxis by promoting NOX2-dependent superoxide production. Trem1-deficient peritoneal neutrophils show impaired NOX2-dependent superoxide production (measured by EPR spectroscopy) and reduced oxygen consumption. TREM-1-deficient neutrophils have impaired directional migration toward fMLP and zymosan-activated serum. TREM-1 regulates neutrophil migratory properties in part by promoting AKT activation and NOX2-dependent superoxide production.\",\n      \"method\": \"Trem1 knockout mice; electron paramagnetic resonance spectroscopy for superoxide; Clark electrode for oxygen consumption; directional migration assay; AKT phosphorylation by Western blot\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with multiple orthogonal mechanistic readouts (EPR, Clark electrode, migration, Western blot); single lab, comprehensive mechanistic dissection\",\n      \"pmids\": [\"30667543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TREM-1 triggers microglial pyroptosis via activating NLRP3 inflammasome following subarachnoid hemorrhage. Recombinant TREM-1 (mimic) worsened outcomes, while LP17 antagonist ameliorated pyroptosis by diminishing GSDMD-N and IL-1β production in microglia. Mechanistically confirmed both in vivo (SAH mouse model) and in vitro.\",\n      \"method\": \"Intranasal LP17 administration; recombinant TREM-1 administration; SAH mouse model; Western blot for NLRP3, caspase-1, GSDMD, GSDMD-N, IL-1β; in vitro microglial cultures\",\n      \"journal\": \"Translational stroke research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological gain- and loss-of-function in vivo and in vitro with protein-level mechanistic endpoints; single lab\",\n      \"pmids\": [\"32862402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Extracellular CIRP (eCIRP) activates TREM-1 on neutrophils, which generates ICAM-1+ neutrophils. ICAM-1+ neutrophils then promote NET formation via Rho GTPase activation. TREM-1-/- neutrophils or LP17-pretreated neutrophils showed significantly decreased ICAM-1 expression after rmCIRP treatment. Blockade of ICAM-1 significantly decreased Rho activation and NET formation.\",\n      \"method\": \"TREM-1-/- mice; LP17 pharmacological inhibition; rmCIRP injection; flow cytometry; Rho activation assay; NET quantification; ICAM-1 blocking antibody\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and pharmacological inhibition with defined downstream signaling (Rho/ICAM-1/NETosis); single lab, multiple orthogonal methods\",\n      \"pmids\": [\"32506691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TREM-1 activation in macrophages induces endoplasmic reticulum stress through the IRE-1α/XBP-1s pathway. Agonistic anti-TREM-1 antibody increased expression of ER stress markers (ATF6, PERK, IRE-1α, XBP-1s) and pro-inflammatory cytokines. Inhibiting IRE-1α/XBP-1s with STF-083010 or XBP-1 silencing attenuated TREM-1-induced cytokine production. TREM-1 blockade (LR12) ameliorated ER stress in vitro and in vivo.\",\n      \"method\": \"Agonistic anti-TREM-1 antibody; STF-083010 IRE-1α inhibitor; XBP-1 siRNA silencing; 4-PBA ER stress inhibitor; Western blot; primary macrophage cultures; LPS-induced ALI mouse model\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — agonist antibody plus pathway inhibitors plus gene silencing with multiple protein-level readouts; single lab\",\n      \"pmids\": [\"33957479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Tryptophanyl-tRNA synthetase 1 (WARS1) activates TREM-1 expression at both mRNA and protein levels via TLR2 and TLR4, mediated by both MyD88 and TRIF. Targeted deletion of TLR4, TLR2, MyD88, and TRIF abrogated TREM-1 activation. WARS1 promoted TREM-1 downstream phosphorylation of DAP12, Syk, and AKT. Knockdown of TREM-1 or inhibition of Syk suppressed the inflammatory signaling loop (p38 MAPK, ERK, NF-κB), reducing cytokine production.\",\n      \"method\": \"TLR4/TLR2/MyD88/TRIF knockout cells; TREM-1 knockdown; Syk kinase inhibitor; Western blot for DAP12, Syk, AKT phosphorylation; cytokine ELISA\",\n      \"journal\": \"Biomolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic KO cell lines plus TREM-1 knockdown with defined phosphoprotein readouts; single lab, multiple orthogonal approaches\",\n      \"pmids\": [\"32899943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TREM-1 orchestrates angiotensin II-induced monocyte trafficking and promotes abdominal aortic aneurysm. TREM-1 on Ly6Chi monocytes is activated by AngII via AT1R signaling. Antibody-mediated TREM-1 stimulation exacerbated Ly6Chi monocyte aorta infiltration via CD62L upregulation. Trem1 gene deletion attenuated aortic inflammation (reduced Il1b, Tnfa, Mmp2, Mmp9 mRNA) and macrophage content.\",\n      \"method\": \"Apoe-/-Trem1-/- mice; AngII-induced AAA model; LR12 pharmacological blockade; anti-TREM-1 stimulating antibody; flow cytometry; qRT-PCR\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO, pharmacological inhibition, and gain-of-function (agonist antibody) in the same model; multiple orthogonal methods\",\n      \"pmids\": [\"33258804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TREM-1 regulates macrophage M1 polarization via the STAT3/HIF-1α signaling pathway. Knockdown of Trem1 in RAW 264.7 cells decreased M1 polarization and increased M2 polarization; overexpression had the opposite effect. Trem1 knockout mice showed limited macrophage infiltration and decreased M1 gene expression in periodontitis lesions.\",\n      \"method\": \"Trem1 siRNA knockdown and overexpression in RAW 264.7 macrophages; Trem1 KO mice; flow cytometry; Western blotting; RT-qPCR; RNA sequencing identifying STAT3/HIF-1α pathway\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO in vivo plus loss- and gain-of-function in vitro with pathway identification by RNA-seq; single lab\",\n      \"pmids\": [\"34719965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TREM-1 cooperates with diminished DNA damage response to promote pre-leukemia stem cell (pre-LSC) expansion in Fanconi anemia. shRNA knockdown of Trem1 in Fanca-/- pre-LSCs improved leukemia-related survival but did not affect DDR or genomic instability, placing TREM-1 downstream or parallel to DDR in leukemogenic transformation.\",\n      \"method\": \"Trem1 shRNA knockdown; Fanca-/- mouse model; in vivo transplantation; survival analysis; gene expression profiling\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined in vivo phenotype and epistasis analysis; single lab\",\n      \"pmids\": [\"27568523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TREM-1 induces cardiomyocyte pyroptosis via NLRP3 inflammasome activation through the SMC4/NEMO pathway in sepsis. TREM-1 and SMC4 were found to interact closely. Inhibition of TREM-1 or SMC4 prevented NLRP3 upregulation and decreased Gasdermin-D, IL-1β and caspase-1 cleavage in HL-1 cardiomyocytes. LR12 in CLP mice decreased NLRP3 expression and attenuated pyroptosis, improving cardiac function and survival.\",\n      \"method\": \"Co-immunoprecipitation (TREM-1/SMC4 interaction); siRNA inhibition of TREM-1 and SMC4; LPS/nigericin-stimulated HL-1 cells; CLP sepsis mouse model; LR12 peptide; Western blot\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifying SMC4 interaction plus in vitro and in vivo functional validation; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"36181338\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TREM-1 exacerbates pulmonary fibrosis by promoting alveolar epithelial cell (AEC) senescence. TREM-1 was upregulated in AECs (not just macrophages) in bleomycin-treated mice and correlated with senescence markers. Agonistic TREM-1 antibody exacerbated BLM-induced senescence in MLE12 cells; blockade with LR12 reduced p16, p21, p53, γ-H2AX expression and attenuated fibrosis.\",\n      \"method\": \"LR12 prophylactic and therapeutic blockade; agonistic TREM-1 antibody in MLE12 cells; BLM-induced PF mouse model; Western blot for senescence markers; histology\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function (agonist antibody) and loss-of-function (LR12) in both in vitro and in vivo models with protein-level mechanistic readouts; single lab\",\n      \"pmids\": [\"36330909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TREM-1 activation in macrophages promotes NLRP3 inflammasome activation through metabolic reprogramming: TREM-1 activation enhances glycolysis and inhibits oxidative phosphorylation via the PI3K/AKT/mTOR pathway, leading to HIF-1α accumulation and nuclear translocation, which drives glycolysis-dependent NLRP3/caspase-1 activation. Inhibiting mTOR, HIF-1α, or glycolysis (2-DG) suppressed TREM-1-induced NLRP3 activation.\",\n      \"method\": \"TREM-1 agonist antibody; 2-deoxyglucose glycolysis inhibition; mTOR inhibitor rapamycin; HIF-1α inhibitor; glucose consumption assay; Western blot; LPS-induced ALI mouse model; LR12 blockade\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway inhibitors combined with agonist activation establishing metabolic-to-inflammasome signaling axis; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"36594089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Endothelial TREM-1 signals via SYK/β-catenin pathway to regulate blood-brain barrier integrity after intracerebral hemorrhage. TREM-1 activation reduces β-catenin, claudin-5, and ZO-1 expression. SYK activation CRISPR abolished the beneficial effect of TREM-1 blockade on junction molecules; the SYK inhibitor R406 reversed the impact of TREM-1 agonist on β-catenin, claudin-5, and ZO-1 downregulation.\",\n      \"method\": \"LP17 intranasal administration; SYK activation CRISPR intracerebroventricularly; anti-TREM-1 agonist IgG; SYK inhibitor R406; ICH collagenase mouse model; Western blot; BBB permeability assay\",\n      \"journal\": \"CNS neuroscience & therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain- and loss-of-function with SYK genetic activation and pharmacological inhibition establishing pathway; single lab\",\n      \"pmids\": [\"37170484\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"eCIRP activates TREM-1 on renal endothelial cells to induce AKI. TREM-1-/- mice had attenuated AKI and reduced ICAM-1 expression in renal tissue after rmCIRP injection. TREM-1 inhibitory peptide M3 attenuated human renal glomerular endothelial cell activation (cytokine production and sTREM-1 release) after eCIRP stimulation.\",\n      \"method\": \"TREM-1-/- mice; rmCIRP injection; M3 inhibitory peptide; primary human renal glomerular endothelial cell culture; serum BUN/creatinine/NGAL measurement; mRNA and protein expression\",\n      \"journal\": \"Frontiers in physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and pharmacological inhibition in vivo and in vitro; multiple injury biomarkers; single lab\",\n      \"pmids\": [\"36246143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREM-1 triggers macrophage necroptosis through mTOR-dependent mitochondrial fission during ALI. TREM-1 activation (agonist anti-TREM-1 Ab) induced necroptosis in macrophages. mTOR signaling promotes TREM-1-mediated DRP1Ser616 phosphorylation, causing surplus mitochondrial fission leading to necroptosis. Inhibiting mTOR (rapamycin), DRP1 (Mdivi-1), or RIPK3 (GSK872) all reduced TREM-1-triggered necroptosis.\",\n      \"method\": \"Agonist anti-TREM-1 antibody; RIPK3 inhibitor GSK872; DRP1 inhibitor Mdivi-1; mTOR inhibitor rapamycin; LR12 in LPS-induced ALI mice; Western blot for DRP1Ser616 phosphorylation; necroptosis assays\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — agonist plus multiple pathway inhibitors establishing mTOR-DRP1-necroptosis axis; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"36879273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Accumulated lipid droplets (LDs) in microglia co-localize with TREM1, resulting in TREM1 buildup. TREM1 accumulation in turn aggravates HG-induced lipophagy damage and promotes neuroinflammatory cascades via NLRP3 inflammasome. LP17 blockade of TREM1 inhibited LD and TREM1 accumulation and reduced hippocampal neuronal inflammatory damage.\",\n      \"method\": \"Co-immunoprecipitation (LDs/TREM1 co-localization); db/db and HFD/STZ mouse models; LP17 pharmacological blockade; HG-treated BV2, HMC3 and primary microglia; Western blot; immunofluorescence; behavioral tests\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus pharmacological blockade in multiple in vivo models with defined mechanistic pathway; single lab\",\n      \"pmids\": [\"37204119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREM1 promotes gastric cancer progression through NETs-mediated M2 macrophage polarization. TREM1 deficiency hindered tumor growth, reduced neutrophil infiltration, reduced NETs formation, and stimulated M1 (rather than M2) macrophage polarization. DNase-1 (NETs degrader) counteracted the impacts of TREM1 on GC, placing TREM1 upstream of NETs in this pathway.\",\n      \"method\": \"TREM1 KO and knock-in GC mice; MNNG-induced GC model; DNase-1 treatment; flow cytometry for macrophage polarization; immunofluorescence and Western blot for NETs markers; IHC\",\n      \"journal\": \"Digestive and liver disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO/KI plus epistasis experiment with DNase-1 placing TREM1 upstream of NETs; single lab\",\n      \"pmids\": [\"38151453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREM1 in microglia is upregulated by HIV Tat through a TLR4/TICAM1/COX-2/PGE synthase/PGE2-dependent pathway. TREM1 silencing in HIV-infected microglia induces cell death without increased viral or pro-inflammatory cytokine expression.\",\n      \"method\": \"TREM1 siRNA silencing in HIV-infected human microglia; TLR4 blocking; COX-2 and PGE2 pathway inhibitors; apoptosis assays; cytokine measurement\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic silencing plus pharmacological pathway inhibitors establishing the upstream regulatory mechanism; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"37326481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Trem1 deficiency prevents age-dependent changes in myeloid metabolism and inflammation. Trem1-deficient microglia are resistant to amyloid-β42 oligomer-induced bioenergetic changes in vitro. Trem1 haploinsufficiency in 5XFAD mice prevents spatial memory loss, preserves homeostatic microglial morphology, reduces neuritic dystrophy and disease-associated microglial transcriptomic signature changes. In aging APPSwe mice, Trem1 deficiency prevents hippocampal memory decline while restoring synaptic mitochondrial function and cerebral glucose uptake. TREM1 colocalizes with Iba1+ cells around amyloid plaques in postmortem AD brain.\",\n      \"method\": \"Trem1 KO and haploinsufficiency in 5XFAD and APPSwe mouse models; metabolomics (ribose 5-phosphate); in vitro bioenergetics assay; spatial memory testing; microglial morphology analysis; transcriptomics; PET imaging for glucose uptake; postmortem AD brain immunohistochemistry\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models (KO, haploinsufficiency) in two different AD mouse models plus in vitro mechanistic assays and postmortem human validation; multiple orthogonal methods\",\n      \"pmids\": [\"38539014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TREM1 modulates M1 macrophage polarization via STAT3/HIF-1α axis. In microglia, TREM1 regulates NLRP3 activation via the NF-κB pathway: TREM1 overexpression activates NF-κB, upregulates NLRP3 components and pro-inflammatory cytokines; NF-κB inhibitor PDTC reversed this. TREM1 knockdown attenuated LPS-induced NF-κB pathway activation.\",\n      \"method\": \"TREM1 siRNA knockdown; TREM1 overexpression plasmid; NF-κB inhibitor PDTC; LPS-treated BV2 cells; Western blotting; immunofluorescence; NTG-induced chronic migraine mouse model; LR12 inhibition\",\n      \"journal\": \"The journal of headache and pain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function and gain-of-function with pathway inhibitor rescue; in vitro and in vivo; single lab\",\n      \"pmids\": [\"38177990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TREM1 aggravates microglial ferroptosis through the PERK pathway of endoplasmic reticulum stress in diabetes-associated cognitive impairment. High glucose activates the PERK-ERS pathway; TREM1 inhibition with LP17 or PERK inhibitor GSK2606414 reversed ferroptosis (iron accumulation, GSH/GSSG reduction, lipid peroxidation, ROS) in BV2/HMC3 microglia and in vivo.\",\n      \"method\": \"LP17 pharmacological blockade; PERK inhibitor GSK2606414; HG-treated BV2 and HMC3 cells; HFD/STZ mouse model; Prussian blue staining for iron; Western blot; transmission electron microscopy; Y-maze and NOR behavioral tests\",\n      \"journal\": \"Experimental neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological blockade of TREM1 and PERK showing pathway interdependence; in vitro and in vivo; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"39461708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In glioblastoma, hypoxia-induced TREM1 in M2-like TAMs promotes mesenchymal-like states of glioma stem cells by modulating TGFβ2 secretion, which activates TGFβR/SMAD2/3 signaling in GSCs. TREM1 expression in TAMs is transcriptionally regulated by HIF-1α under hypoxic conditions and promotes immunosuppressive TAM polarization via the TLR2/AKT/mTOR/c-MYC axis.\",\n      \"method\": \"HIF-1α ChIP; TREM1 overexpression and knockdown in TAMs; TGFβ2 neutralization; SMAD2/3 Western blot; co-culture of TAMs and GSCs; TLR2/AKT/mTOR pathway inhibitors\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptional regulation established by ChIP, downstream TGFβ2/SMAD pathway by co-culture and pathway inhibitors; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"38479552\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TREM-1 expression in macrophages in response to LPS and Pseudomonas aeruginosa is inhibited by prostaglandins PGD2, PGJ2, and 15-dPGJ2. This inhibition is independent of PGD2 receptors and PPARγ, but occurs through activation of Nrf2 and inhibition of NF-κB.\",\n      \"method\": \"Macrophage cell line treated with prostaglandins; PGD2 receptor antagonists; PPARγ antagonist/agonist; Nrf2 activation assay; NF-κB inhibition assay; TREM-1 expression by Western blot and flow cytometry\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection of pathway with receptor antagonists and transcription factor assays; single lab, multiple orthogonal approaches\",\n      \"pmids\": [\"20797396\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TREM-1 is crucial for macrophage polarization toward M1 phenotype. Kidney lysates from nephritic kidneys triggered TREM-1-dependent M1 polarization ex vivo. GM-CSF-derived M1 macrophages express higher levels of TREM-1 than M-CSF-derived cells. TREM-1 cross-linking strengthens induction of iNOS and GM-CSF in M1 macrophages.\",\n      \"method\": \"Ex vivo macrophage stimulation with nephritic kidney lysates; Trem-1 blocking antibody; ureteral obstruction mouse model; TREM-1 agonistic cross-linking; Western blot; flow cytometry; histology\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ex vivo functional assay plus in vivo model with blocking and agonistic experiments; single lab\",\n      \"pmids\": [\"24918157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Rheumatoid arthritis synovial fibroblasts (RASF) promote TREM-1 expression in CD14+ monocytes via COX-2/PGE2/EP2,4 signaling. Soluble factors (not direct cell contact) mediate this effect, as shown by transwell assay. COX-2 inhibitors, COX-2 siRNA, and EP1-4 antagonists each abrogated RASF-promoted TREM-1 upregulation in monocytes.\",\n      \"method\": \"RASF-monocyte co-culture; transwell assay; COX-2 siRNA; COX-2 inhibitors; EP1-4 antagonists; PGE2 ELISA; TREM-1 flow cytometry\",\n      \"journal\": \"Arthritis research & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transwell assay establishing soluble mediator requirement plus multiple pharmacological and genetic interventions targeting COX-2/PGE2/EP axis; single lab\",\n      \"pmids\": [\"31287012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TREM-1 activation alleviates hyperoxia-induced lung injury in neonatal mice through downregulating RIPK3-mediated necroptosis and NLRP3 inflammasome activation. TREM-1 siRNA or Trem1 gene deletion enhanced lung inflammation and mortality under hyperoxia. Agonistic TREM-1 antibody treatment decreased lung inflammation, improved alveolarization, and diminished RIPK3 expression.\",\n      \"method\": \"Trem1 siRNA; Trem1 KO mice; agonistic TREM-1 antibody; neonatal hyperoxia model; Western blot for RIPK3, NLRP3; histology; survival analysis\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and gain-of-function (agonist antibody) with mechanistic pathway readouts; single lab\",\n      \"pmids\": [\"30281332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LXR, RXR, RAR, and VDR nuclear receptor ligands induce TREM-1 expression on dendritic cells. TREM-1 triggering induced by retinoids increased TNFα and IL-1β release, establishing an active inflammatory role for NRL-activated TREM-1+ DCs.\",\n      \"method\": \"Transcriptomic profiling of DCs treated with 22R-HC; TREM-1 protein expression assay; cytokine ELISA after TREM-1 triggering; RXR/RAR/VDR ligand treatment; Trem-1 bone marrow chimera mouse tumor model\",\n      \"journal\": \"Oncoimmunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptomics plus functional cytokine assays plus in vivo tumor model; single lab, multiple approaches\",\n      \"pmids\": [\"30723587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREM1 agonism via afucosylated humanized anti-TREM1 antibody (PY159, with enhanced FcγR binding) induces TREM1 signaling leading to upregulation of costimulatory molecules on monocytes/macrophages, production of pro-inflammatory cytokines and chemokines, and enhancement of T cell activation in vitro. Anti-mouse TREM1 antibody PY159m promoted antitumor efficacy in syngeneic tumor models.\",\n      \"method\": \"Anti-TREM1 agonist antibody (PY159); cytokine/chemokine measurement; costimulatory molecule expression by flow cytometry; T cell activation assay; syngeneic mouse tumor models\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — agonist antibody with multiple in vitro and in vivo functional readouts; single lab\",\n      \"pmids\": [\"37647386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LPS induces TREM-1-dependent HIF-1α expression in human HaCaT keratinocytes via the PI3K/Akt pathway. TREM-1 siRNA silencing suppressed LPS-induced PI3K/Akt phosphorylation and HIF-1α expression. PI3K inhibitor wortmannin blocked HIF-1α induction without affecting TREM-1 expression itself, placing TREM-1 upstream of PI3K/Akt/HIF-1α.\",\n      \"method\": \"TREM-1 siRNA; PI3K inhibitor wortmannin; LPS-stimulated HaCaT keratinocytes; Western blot for pAkt, HIF-1α, TREM-1; immunofluorescence\",\n      \"journal\": \"Cell biology international\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — siRNA and pharmacological inhibitor in a single cell line with one lab; no genetic KO or in vivo validation\",\n      \"pmids\": [\"27743451\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TREM-1 is a cell surface immunoreceptor expressed on myeloid cells that constitutively associates with the ITAM-bearing adapter DAP12; upon activation by multimerization/ligand clustering, TREM-1 signals through DAP12 phosphorylation, SYK, PI3K/AKT, p38MAPK, and ERK to amplify TLR-initiated pro-inflammatory responses including NF-κB, NLRP3 inflammasome/pyroptosis, ER stress (IRE-1α/XBP-1s), and metabolic reprogramming (mTOR/HIF-1α/glycolysis), while also regulating macrophage M1 polarization, neutrophil chemotaxis via NOX2-dependent superoxide, microglial phagocytosis of amyloid-β, mitochondrial integrity, and cell death pathways (necroptosis via mTOR/DRP1/RIPK3 and ferroptosis via PERK) across multiple tissue and disease contexts.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TREM-1 is a myeloid cell-surface immunoreceptor that amplifies innate inflammatory responses by partnering with the ITAM-bearing adapter DAP12, which it constitutively associates with and requires to transduce signals driving cytokine and chemokine production, reactive oxygen species generation, degranulation and phagocytosis [#0]. Receptor activation is triggered by ligand-induced clustering: the TREM-1 ectodomain homooligomerizes in a concentration-dependent manner, DAP12 stabilizes surface expression and multimerization, and the degree of aggregation scales with Ca2+ flux, ROS, and cytokine output [#8]. Downstream of DAP12, TREM-1 recruits SYK and signals through PI3K/AKT, PLC, p38MAPK and ERK to amplify inflammation, frequently in physical and functional cooperation with the TLR4/LPS receptor complex with which it co-localizes [#2, #3, #11, #18]. Through these axes TREM-1 converges on NF-\\u03baB and the NLRP3/caspase-1 inflammasome, and engages metabolic reprogramming via PI3K/AKT/mTOR-driven HIF-1\\u03b1 accumulation and glycolysis to license inflammasome activation and M1 macrophage polarization [#24, #20, #32]. TREM-1 also couples to multiple regulated cell-death programs, including GSDMD-dependent pyroptosis, mTOR/DRP1/RIPK3-dependent necroptosis, and PERK-ER-stress-dependent ferroptosis [#11, #27, #33]. Across disease models, genetic deletion or peptide blockade (LR12, LP17) of TREM-1 attenuates pathology in myocardial infarction, atherosclerosis, abdominal aortic aneurysm, liver fibrosis, stroke, and Alzheimer's disease, where it additionally governs microglial bioenergetics and amyloid-\\u03b2 handling [#4, #5, #6, #9, #12, #19, #31, #7]. Soluble TREM-1 is released into plasma during acute inflammatory injury [#4].\",\n  \"teleology\": [\n    {\n      \"year\": 2007,\n      \"claim\": \"Established the core signaling architecture: how a receptor lacking intrinsic signaling motifs transduces activation into inflammatory output.\",\n      \"evidence\": \"Biochemical and functional assays in monocytes and neutrophils showing constitutive TREM-1/DAP12 association and DAP12 phosphorylation-dependent effector functions\",\n      \"pmids\": [\"18192027\", \"23108097\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous physiological ligand not identified\", \"Stoichiometry of the TREM-1/DAP12 complex not resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Provided early evidence for a cellular TREM-1 ligand, addressing what physically engages the receptor to amplify neutrophil responses.\",\n      \"evidence\": \"Recombinant TREM-1 fusion protein binding to platelets and TREM-1 blockade in platelet/PMN co-culture\",\n      \"pmids\": [\"17452516\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular identity of the platelet ligand not defined\", \"Single lab; binding shown only with a fusion protein\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined the proximal kinase requirements for TREM-1-induced oxidative burst and its synergy with TLR4.\",\n      \"evidence\": \"Pharmacological inhibitors of PI3K/PLC/p38MAPK and Western blot of AKT/ERK phosphorylation in human PMN\",\n      \"pmids\": [\"20375613\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Inhibitor-based; direct kinase substrates not mapped\", \"Relative ordering of PI3K, PLC and MAPK arms unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed TREM-1 is physically and functionally integrated with the TLR4 receptor complex, explaining its amplification of LPS responses.\",\n      \"evidence\": \"Reciprocal blocking antibodies and co-localization immunofluorescence in human neutrophils\",\n      \"pmids\": [\"21393102\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Co-localization does not prove direct binary interaction\", \"Single lab, primary cells only\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Established TREM-1 as a causal driver of inflammatory tissue injury in vivo, moving beyond correlation in cardiac disease.\",\n      \"evidence\": \"Trem-1 knockout plus LR12 pharmacological inhibition in myocardial infarction models with imaging and functional readouts\",\n      \"pmids\": [\"25840803\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell type responsible (neutrophil vs monocyte) not isolated\", \"Trigger for TREM-1 upregulation in ischemic myocardium undefined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined a pro-atherogenic role and a concrete mechanism via CD36 upregulation and foam-cell formation.\",\n      \"evidence\": \"Two independent Trem1/Apoe double-KO models, bone marrow chimeras, and LR12 blockade with histology and gene expression\",\n      \"pmids\": [\"28007141\", \"27762264\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct link between TREM-1 signaling and CD36 transcription not mapped\", \"Dyslipidemic serum factors that synergize with TREM-1 not identified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealed a beneficial, phagocytic role in CNS by showing TREM1 drives microglial clearance of amyloid-\\u03b2.\",\n      \"evidence\": \"Trem1 knockdown/overexpression and agonist antibody in primary microglia and APP/PSEN1 mice with behavioral testing\",\n      \"pmids\": [\"27670763\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation with later detrimental microglial roles unresolved\", \"Receptor coupling to phagocytic machinery not detailed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolved the activation mechanism: TREM-1 is switched on by ectodomain oligomerization/clustering rather than monomeric ligation.\",\n      \"evidence\": \"Native mass spectrometry of ectodomain plus Ca2+/ROS/cytokine assays in monocytes and neutrophils; LR12 limits multimerization\",\n      \"pmids\": [\"29568119\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic structure of the oligomer not solved\", \"Endogenous clustering ligand still unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated a cell-autonomous Kupffer cell role for TREM-1 in liver injury and stellate cell activation.\",\n      \"evidence\": \"Trem1 KO with Kupffer cell reconstitution in CCl4 chronic liver injury model\",\n      \"pmids\": [\"30137027\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct signal from Kupffer cells to stellate cells not defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked TREM-1 to autophagy and ER stress (UPR) regulation in intestinal inflammation.\",\n      \"evidence\": \"LR12 and Trem-1 KO in DSS colitis with Western blots of autophagy/UPR markers and microbiota sequencing\",\n      \"pmids\": [\"28961797\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal direction between UPR markers and inflammation correlative\", \"Single lab, marker-level readouts\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified SYK as a direct interactor coupling TREM-1 to CARD9/NF-\\u03baB and NLRP3/GSDMD-driven pyroptosis in microglia.\",\n      \"evidence\": \"Co-IP of TREM-1/SYK plus pathway Western blots in MCAO model and microglial cultures with LP17 inhibition\",\n      \"pmids\": [\"31324751\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Co-IP without reciprocal/structural validation\", \"Whether SYK binding is DAP12-mediated not shown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established a gut-brain inflammatory axis whereby stroke-induced intestinal TREM1 drives barrier breakdown and bacterial translocation.\",\n      \"evidence\": \"Genetic KO, pharmacological inhibition, and anti-TREM1 PET imaging in MCAO stroke model\",\n      \"pmids\": [\"31263278\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signal inducing intestinal TREM1 beyond noradrenergic input incomplete\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed a context-dependent pro-survival role: TREM1 maintains mitochondrial integrity to protect HIV-infected macrophages from apoptosis.\",\n      \"evidence\": \"TREM1 siRNA in HIV-infected macrophages with BCL2-family Western blots, membrane potential, cytochrome c and caspase-9 readouts\",\n      \"pmids\": [\"31719184\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TREM1 controls BCL2-family balance mechanistically unclear\", \"siRNA only; no in vivo confirmation\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined a mechanism for TREM-1 control of neutrophil chemotaxis via AKT-driven NOX2 superoxide production.\",\n      \"evidence\": \"Trem1 KO neutrophils with EPR superoxide measurement, oxygen consumption, migration assays and AKT Western blot\",\n      \"pmids\": [\"30667543\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct link between NOX2 superoxide and directional migration not fully separated from AKT\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected TREM-1 to NET formation through eCIRP-induced ICAM-1+ neutrophils and Rho GTPase activation.\",\n      \"evidence\": \"TREM-1 KO and LP17 with rmCIRP, flow cytometry, Rho activation and NET quantification\",\n      \"pmids\": [\"32506691\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether eCIRP binds TREM-1 directly not established\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed TREM-1 activation induces ER stress via the IRE-1\\u03b1/XBP-1s arm to amplify cytokine production.\",\n      \"evidence\": \"Agonist antibody plus IRE-1\\u03b1 inhibitor and XBP-1 silencing in macrophages and LPS-ALI model\",\n      \"pmids\": [\"33957479\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking surface receptor to UPR sensors unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified WARS1 as an upstream inducer of TREM-1 acting through TLR2/TLR4-MyD88/TRIF, and confirmed the DAP12-SYK-AKT signaling loop.\",\n      \"evidence\": \"TLR/MyD88/TRIF KO cells, TREM-1 knockdown and SYK inhibitor with phosphoprotein Western blots\",\n      \"pmids\": [\"32899943\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether WARS1 acts as a TREM-1 ligand or only an inducer unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated TREM-1 drives microglial pyroptosis through NLRP3 inflammasome activation after subarachnoid hemorrhage.\",\n      \"evidence\": \"Recombinant TREM-1 and LP17 antagonist in SAH model with GSDMD-N/IL-1\\u03b2 Western blots\",\n      \"pmids\": [\"32862402\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pharmacological-only manipulation; no genetic KO\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed TREM-1 orchestrates AngII-driven Ly6Chi monocyte trafficking and aneurysm formation via CD62L upregulation.\",\n      \"evidence\": \"Apoe-/-Trem1-/- mice, LR12 blockade and agonist antibody in AngII-AAA model\",\n      \"pmids\": [\"33258804\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct link between AT1R and TREM-1 activation undefined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placed TREM-1 on the STAT3/HIF-1\\u03b1 axis governing M1 versus M2 macrophage polarization.\",\n      \"evidence\": \"Trem1 knockdown/overexpression in RAW264.7, Trem1 KO mice and RNA-seq in periodontitis lesions\",\n      \"pmids\": [\"34719965\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct TREM-1 to STAT3 coupling not demonstrated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified a TREM-1 role in leukemic transformation, acting downstream or parallel to the DNA damage response in Fanconi anemia pre-LSCs.\",\n      \"evidence\": \"Trem1 shRNA in Fanca-/- pre-LSCs with transplantation and survival analysis\",\n      \"pmids\": [\"27568523\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Effector pathway driving pre-LSC expansion unidentified\", \"shRNA knockdown only\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established metabolic reprogramming as the link between TREM-1 and inflammasome activation via PI3K/AKT/mTOR-HIF-1\\u03b1-glycolysis.\",\n      \"evidence\": \"Agonist antibody with mTOR, HIF-1\\u03b1 and glycolysis (2-DG) inhibitors plus glucose consumption assays in LPS-ALI model\",\n      \"pmids\": [\"36594089\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Inhibitor-based; direct metabolic flux mapping limited\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Implicated TREM-1 in cardiomyocyte pyroptosis through a SMC4/NEMO-NLRP3 axis in sepsis.\",\n      \"evidence\": \"Co-IP of TREM-1/SMC4 and siRNA in HL-1 cells with LR12 in CLP sepsis model\",\n      \"pmids\": [\"36181338\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Co-IP without reciprocal validation\", \"How a myeloid receptor functions in cardiomyocytes unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended TREM-1 function beyond immune cells, showing it drives alveolar epithelial cell senescence in pulmonary fibrosis.\",\n      \"evidence\": \"Agonist antibody and LR12 in MLE12 cells and bleomycin model with senescence-marker Western blots\",\n      \"pmids\": [\"36330909\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of epithelial TREM-1 expression and signaling undefined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined endothelial TREM-1 signaling through SYK/\\u03b2-catenin controlling blood-brain barrier junction proteins after hemorrhage.\",\n      \"evidence\": \"LP17, SYK-activation CRISPR and SYK inhibitor R406 in ICH model with junction-protein Western blots\",\n      \"pmids\": [\"37170484\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Connection between SYK and \\u03b2-catenin not mechanistically detailed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended the eCIRP-TREM-1 axis to renal endothelial cells driving acute kidney injury.\",\n      \"evidence\": \"TREM-1 KO and M3 inhibitory peptide with rmCIRP in mice and human renal endothelial cells\",\n      \"pmids\": [\"36246143\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct eCIRP-TREM-1 binding not shown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Linked TREM-1 to macrophage necroptosis via mTOR-dependent DRP1 phosphorylation and RIPK3.\",\n      \"evidence\": \"Agonist antibody with rapamycin, Mdivi-1 and GSK872 in macrophages and LPS-ALI model; DRP1Ser616 Western blots\",\n      \"pmids\": [\"36879273\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Inhibitor-based; how TREM-1 engages mTOR-DRP1 directly unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Connected lipid droplet accumulation to TREM1 buildup, impaired lipophagy, and NLRP3-driven neuroinflammation in diabetic microglia.\",\n      \"evidence\": \"Co-IP/co-localization of LDs and TREM1 with LP17 in db/db and HFD/STZ models\",\n      \"pmids\": [\"37204119\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Nature of LD-TREM1 association not defined\", \"Pharmacological-only manipulation\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed TREM1 promotes gastric cancer progression by driving NET-mediated M2 macrophage polarization.\",\n      \"evidence\": \"TREM1 KO/knock-in mice with DNase-1 epistasis in MNNG-induced gastric cancer model\",\n      \"pmids\": [\"38151453\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signal linking TREM1 to NET induction in tumors undefined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined an upstream regulatory cascade in which HIV Tat induces microglial TREM1 via TLR4/TICAM1/COX-2/PGE2.\",\n      \"evidence\": \"TREM1 siRNA with TLR4 blocking and COX-2/PGE2 inhibitors in HIV-infected human microglia\",\n      \"pmids\": [\"37326481\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether silencing-induced death reflects loss of survival signaling unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Provided therapeutic proof-of-concept that TREM1 agonism reprograms myeloid cells and drives antitumor immunity.\",\n      \"evidence\": \"Afucosylated anti-TREM1 agonist antibody (PY159) with cytokine, costimulation and T-cell assays plus syngeneic tumor models\",\n      \"pmids\": [\"37647386\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism distinguishing beneficial vs pathogenic TREM1 activation context-dependent\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established that TREM1 governs age- and amyloid-dependent microglial metabolism and cognitive decline, validated in human AD brain.\",\n      \"evidence\": \"Trem1 KO and haploinsufficiency in 5XFAD and APPSwe mice with metabolomics, bioenergetics, transcriptomics, PET and postmortem IHC\",\n      \"pmids\": [\"38539014\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation with the earlier phagocytosis-promoting role in AD unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Reinforced TREM1 control of M1 polarization and NF-\\u03baB-dependent NLRP3 activation in microglia in chronic migraine.\",\n      \"evidence\": \"TREM1 knockdown/overexpression with NF-\\u03baB inhibitor PDTC in BV2 cells and NTG migraine model with LR12\",\n      \"pmids\": [\"38177990\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct receptor-to-NF-\\u03baB coupling not isolated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed hypoxia/HIF-1\\u03b1-induced TREM1 in glioblastoma TAMs promotes glioma stem cell mesenchymal states via TGF\\u03b22/SMAD signaling.\",\n      \"evidence\": \"HIF-1\\u03b1 ChIP, TREM1 overexpression/knockdown, TGF\\u03b22 neutralization and TAM/GSC co-culture\",\n      \"pmids\": [\"38479552\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"TLR2/AKT/mTOR/c-MYC axis mechanistic links partly inferred\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linked TREM1 to microglial ferroptosis through the PERK arm of ER stress in diabetic cognitive impairment.\",\n      \"evidence\": \"LP17 and PERK inhibitor GSK2606414 in high-glucose BV2/HMC3 cells and HFD/STZ mice with iron and lipid peroxidation readouts\",\n      \"pmids\": [\"39461708\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pharmacological-only; how TREM1 activates PERK unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The endogenous physiological ligand(s) that cluster TREM-1 to initiate signaling, and the structural basis of how oligomerization is relayed through DAP12 to SYK across diverse cell types and opposing (pro-survival vs cell-death) outcomes, remain undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No definitive endogenous agonist ligand identified\", \"No atomic-resolution structure of the activated TREM-1/DAP12 oligomer\", \"Determinants of context-dependent beneficial vs pathogenic outcomes unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 8]},\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 18, 40]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 11, 24]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [11, 27, 33]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [17, 10, 24]}\n    ],\n    \"complexes\": [\"TREM-1/DAP12 receptor complex\", \"TLR4/LPS receptor complex\"],\n    \"partners\": [\"TYROBP\", \"SYK\", \"TLR4\", \"SMC4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}